Cancer evidence library
Non-Hodgkin Lymphoma
PubMed-indexed evidence across major non-Hodgkin lymphoma subtypes and treatment strategies.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Living evidence synopsis
What the current PubMed collection shows.
Alexandria currently organizes 599 non-retracted PubMed-indexed records for Non-Hodgkin Lymphoma. The structured collection includes 15 guideline or consensus records, 76 evidence syntheses/systematic reviews/meta-analyses, and 72 randomized or phase III studies. 118 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 421 of 599 included records.
Evidence data
Research landscape
Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.
Publication activity
Latest 12 represented yearsRecords by publication year
1
1996
1
2011
2
2014
2
2017
1
2018
2
2019
8
2021
11
2022
13
2023
24
2024
75
2025
459
2026
Evidence composition
Study designs
Transparency
Conflict-of-interest reporting
Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.
Abstract result signals
Extracted result direction
Reported outcomes
Numerical results extracted from PubMed abstracts
Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.
Non-pooled ratio measures
Reference = 1.0
Hazard, risk, and odds ratios reported in abstracts
0.250.51.02.04.0
View extracted numerical results 60
| Publication | Outcome | Measure | Reported value | Source |
|---|---|---|---|---|
| Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.Transplantation and cellular therapy · 2026 | not_reported | Odds Ratio | 1.92 95% CI 0.54–6.84 P = 0.317 | PMID 40953732 |
| Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.Transplantation and cellular therapy · 2026 | not_reported | Odds Ratio | 1.76 95% CI 0.71–4.36 P = 0.223 | PMID 40953732 |
| Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.Transplantation and cellular therapy · 2026 | not_reported | Odds Ratio | 1.93 95% CI 0.81–4.57 P=0.136 | PMID 40953732 |
| Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.Transplantation and cellular therapy · 2026 | not_reported | Odds Ratio | 4.0 | PMID 40953732 |
| Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology.Blood advances · 2026 | overall survival | Percentage Comparison | 75.0percent vs 47.0percent P = .008 | PMID 41071951 |
| Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology.Blood advances · 2026 | overall survival | Percentage Comparison | 78.0percent vs 76.0percent P = .008 | PMID 41071951 |
| ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.Leukemia · 2026 | overall survival | Hazard Ratio | 4.51 p = 0.039 | PMID 41145670 |
| ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.Leukemia · 2026 | overall survival | Hazard Ratio | 3.34 p = 0.039 | PMID 41145670 |
| ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.Leukemia · 2026 | overall survival | Hazard Ratio | 6.38 p = 0.039 | PMID 41145670 |
| Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study.Leukemia & lymphoma · 2026 | not_reported | Odds Ratio | 10.2 95% CI 3.3–39.2 | PMID 41178593 |
| Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study.Leukemia & lymphoma · 2026 | not_reported | Odds Ratio | 9.0 95% CI 2.3–45.5 | PMID 41178593 |
| Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.Acta neurologica Belgica · 2026 | not_reported | Hazard Ratio | 0.65 95% CI 0.43–0.98 | PMID 41212511 |
| Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.Acta neurologica Belgica · 2026 | not_reported | Risk Ratio | 1.37 95% CI 1.07–1.76 | PMID 41212511 |
| Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.Acta neurologica Belgica · 2026 | not_reported | Risk Ratio | 1.37 95% CI 1.05–1.79 | PMID 41212511 |
| Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.Acta neurologica Belgica · 2026 | not_reported | Risk Ratio | 1.29 95% CI 0.99–1.68 | PMID 41212511 |
| Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.Acta neurologica Belgica · 2026 | not_reported | Risk Ratio | 1.4 95% CI 1.12–1.77 | PMID 41212511 |
| Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.Acta neurologica Belgica · 2026 | not_reported | Risk Ratio | 1.33 95% CI 0.99–1.78 | PMID 41212511 |
| Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.Acta neurologica Belgica · 2026 | not_reported | Risk Ratio | 1.24 95% CI 0.79–1.94 | PMID 41212511 |
| Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.Acta neurologica Belgica · 2026 | not_reported | Odds Ratio | 5.0 | PMID 41212511 |
| Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Hazard Ratio | 0.72 95% CI 0.47–1.12 | PMID 41260259 |
| Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | adverse events | Percentage Comparison | 54.7percent vs 62.7percent P = 0.046 | PMID 41260259 |
| Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | adverse events | Percentage Comparison | 9.5percent vs 14.2percent P = 0.046 | PMID 41260259 |
| Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.Lancet (London, England) · 2026 | progression-free survival | Hazard Ratio | 0.0 | PMID 41360064 |
| Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026 | progression-free survival | Hazard Ratio | 0.0 | PMID 41371238 |
| Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 | not_reported | Percentage Comparison | 43.0percent vs 92.0percent P = 1 | PMID 41385760 |
| Impact of Achieving Progression-Free Survival 24 on Subsequent Overall Survival in Diffuse Large B-Cell Lymphoma Patients.Cancer science · 2026 | not_reported | Odds Ratio | 2.76 p = 0.004 | PMID 41420335 |
| Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 | not_reported | Percentage Comparison | 42.0percent vs 95.0percent P < .001 | PMID 41428995 |
| Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 | response | Percentage Comparison | 45.0percent vs 96.0percent P < .001 | PMID 41428995 |
| Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.The Lancet. Haematology · 2026 | objective response rate | Risk Ratio | 1.0 | PMID 41448213 |
| Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan.Cancer science · 2026 | adverse events | Odds Ratio | 4.0 | PMID 41457564 |
| Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.Transplantation and cellular therapy · 2026 | not_reported | Hazard Ratio | 0.24 | PMID 41525947 |
| Establishing practical predictors of collection efficiency for optimized chimeric antigen receptor T-cell apheresis.Cytotherapy · 2026 | not_reported | Odds Ratio | 0.416 p = 0.0339 | PMID 41544567 |
| Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 | not_reported | Hazard Ratio | 0.36 p = 0.01 | PMID 41580147 |
| Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.The Lancet. Haematology · 2026 | progression-free survival | Hazard Ratio | 0.0 | PMID 41651641 |
| Risk Factors for Invasive Infection in Febrile Oncology Patients Related to Cancer Type.Pediatric emergency care · 2026 | not_reported | Odds Ratio | 6.006 95% CI 2.459–18.2 | PMID 41661178 |
| Risk Factors for Invasive Infection in Febrile Oncology Patients Related to Cancer Type.Pediatric emergency care · 2026 | not_reported | Odds Ratio | 1.668 95% CI 1.205–2.571 | PMID 41661178 |
| Risk Factors for Invasive Infection in Febrile Oncology Patients Related to Cancer Type.Pediatric emergency care · 2026 | not_reported | Odds Ratio | 1.145 95% CI 1.036–1.267 | PMID 41661178 |
| Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis.Cancer · 2026 | not_reported | Hazard Ratio | 0.75 | PMID 41701615 |
| Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis.Cancer · 2026 | not_reported | Hazard Ratio | 0.51 | PMID 41701615 |
| Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis.Cancer · 2026 | not_reported | Hazard Ratio | 0.47 | PMID 41701615 |
Research transparency
Funding and conflicts of interest
Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.
NCI NIH HHS103
National Natural Science Foundation of China32
NIH HHS16
National Natural Science Foundation of China (National Science Foundation of China)15
Grants-In-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan8
National Cancer Center Research and Development Fund6
Japan Society for the Promotion of Science (JSPS)6
Spanish Foundation for AIDS Research and Prevention5
View records with declared financial or industry relationships 12
Impact of Achieving Progression-Free Survival 24 on Subsequent Overall Survival in Diffuse Large B-Cell Lymphoma Patients.
Wataru Munakata received research funds from Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., and Genmab A/S, and received honoraria from Chugai Pharmaceutical Co. Ltd., outside the submitted work. Ken Ohmachi received honoraria from Chugai Pharmaceutical Co. Ltd., and Genmab A/S, outside the submitted work. Dai Maruyama received research funds from Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Eisai Co. Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Merck and Co. Inc., Zenyaku Holdings Co. Ltd., Sanofi K.K., SymBio Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Abbvie GK, AstraZeneca K.K., Bristol Myers Squibb K.K., Genmab A/S, Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., and Astellas Pharma Inc., and received honoraria from Ono Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Janssen Pharmaceutical K.K., Mundipharma K.K., Eisai Co. Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Merck & Co. Inc., Zenyaku Holdings Co. Ltd., Sanofi K.K., SymBio Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Abbvie GK, AstraZeneca K.K., Bristol‐Myers Squibb K.K., Genmab A/S, and Novartis Pharma K.K., outside the submitted work. Hirokazu Nagai received research funds from Regeneron Pharmaceuticals Inc., Genmab A/S, AstraZeneca K.K., Kyowa Kirin Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corporation, and Eli Lilly and Company, and received honoraria from AbbVie GK, Meiji Seika Pharma Co. Ltd., Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., and Janssen Pharmaceutical K.K., outside the submitted work. The other authors have no financial conflicts of interest to disclose.
PMID 41420335 · 2026Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Martine E.D. Chamuleau . Consulting or Advisory Role: AbbVie (Inst). Research Funding: Bristol Myers Squibb Foundation (Inst), AbbVie (Inst). Travel, Accommodations, Expenses: Janssen (Inst). No other potential conflicts of interest were reported.
PMID 41385760 · 2026Prospective Cohort Study Testing Interventions to Reduce Diagnosis Delay and Treatment Abandonment of Children With Burkitt Lymphoma in Kenya.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Gail H. Vance . Employment: Indiana University Health. Stock and Other Ownership Interests: Lilly. Patrick J. Loehrer . Research Funding: Novartis (Inst), Lilly Foundation (Inst), Taiho Pharmaceutical (Inst). Patents, Royalties, Other Intellectual Property: US PPA/61/499,988 Gene Expression Analysis of Thymic Neoplasms Inventors: Sunil Badve, Yesim Gokmen-Polar, Patrick Loehrer (Inst). Other Relationship: National Cancer InstituteNo other potential conflicts of interest were reported.
PMID 41671528 · 2026Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.
Conflict-of-interest disclosure: A.D. participated in advisory boards for Takeda and AbbVie. B.C. participated in advisory boards for and received honoraria for lectures/educational events from Kite, Gilead, and Novartis. S.B. participated in speakers bureaus for Bristol Myers Squibb (BMS), Gilead, and Novartis; participated on an advisory board for Novartis; and reports travel accommodation expenses from Roche. A.C. participated in advisory boards for Gilead Sciences, Ideogen, Roche, Secura Bio, and Takeda; and reports honoraria for lectures/educational events from AbbVie, Eli Lilly, Gilead Sciences, Incyte, Janssen-Cilag, Novartis, and Takeda. A.D.R. reports consulting fees from Roche, Takeda, Incyte, Kite-Gilead, Novartis, and AbbVie; participated in speakers bureaus for Roche, Kite-Gilead, Janssen, AbbVie, Eli Lilly, Sobi, Incyte, and Recordati Rare Disease; and participated in advisory boards for Takeda, Kite-Gilead, Roche, AbbVie, and Novartis. P.Z. acted as a consultant for Merck Sharp & Dohme (MSD), Eusapharma, and Novartis; participated on advisory boards for ADC Therapeutics, AstraZeneca, BeiGene, BMS, Celltrion, Eusapharma, Gilead, Incyte, Janssen-Cilag, Kyowa Kirin, MSD, Novartis, Roche, Sandoz, Secura Bio, Servier, and Takeda; and participated in speakers bureaus for AstraZeneca, BeiGene, BMS, Celltrion, Eusapharma, Gilead, Incyte, Janssen-Cilag, Kyowa Kirin, MSD, Novartis, Roche, Servier, and Takeda. P. Corradini participated on advisory boards for AbbVie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead/Kite, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin, Nerviano Medical Science, Novartis, Roche, Sanofi, and Takeda; and reports honoraria for lectures from AbbVie, Amgen, Celgene, Gilead/Kite, Janssen, Novartis, Roche, Sanofi, and Takeda. The remaining authors declare no competing financial interests.
PMID 40763273 · 2025Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). David M. Kurtz . Employment: Foresight Diagnostics. Leadership: Foresight Diagnostics. Stock and Other Ownership Interests: Foresight Diagnostics. Consulting or Advisory Role: Roche Molecular Diagnostics, Genentech. Patents, Royalties, Other Intellectual Property: Dr Kurtz has patents pending related to methods for analysis of cell free nucleic acids and methods for treatment selection based on statistical frameworks of clinical outcome. Jason R. Westin . Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, AbbVie, MorphoSys/Incyte, Seagen, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma. Research Funding: Janssen, Novartis, Kite/Gilead, Bristol Myers Squibb, AstraZeneca, MorphoSys/Incyte, ADC Therapeutics, Genentech/Roche, Allogene Therapeutics. Ryan C. Lynch . Honoraria: Merck. Consulting or Advisory Role: Foresight Diagnostics, Seagen, Janssen, AbbVie, ADC Therapeutics, Genentech. Research Funding: Cyteir, Bayer, Incyte, TG Therapeutics, Genentech, Seagen, RAPT Therapeutics, Merck, Janssen Oncology, Allogene Therapeutics. Ajay K. Gopal . Honoraria: Seagen, Pfizer, Gilead Sciences, Janssen Oncology, ADC Therapeutics, Amgen, I-MAB, Actinium Pharmaceuticals, Cellectar, Nurix, Takeda, MorphoSys, Kite/Gilead, Epizyme, TG Therapeutics, Merck. Consulting or Advisory Role: Pfizer, Seagen, Janssen Oncology, Millennium, Gilead Sciences, Nurix, Cellectar, Kite/Gilead, MorphoSys, Incyte, I-MAB, TG Therapeutics, Scitek, Sana Biotechnology, Compliment Cor. Research Funding: Merck (Inst), Bristol Myers Squibb (Inst), Gilead Sciences (Inst), Seagen (Inst), Teva (Inst), Pfizer (Inst), Janssen Oncology (Inst), Millennium (Inst), IgM (Inst), I-MAB (Inst), Takeda (Inst), AstraZeneca (Inst). Stefan K. Alig . Stock and Other Ownership Interests: Bristol Myers Squibb, Fresenius, Gilead Sciences, Regeneron, VIR Biotechnology, Calithera Biosciences, Natera, Affimed Therapeutics, Merck. Consulting or Advisory Role: Foresight Diagnostics. Brian J. Sworder . Stock and Other Ownership Interests: Allogene Therapeutics, CARGO Therapeutics. Consulting or Advisory Role: Foresight Diagnostics, ADC Therapeutics. Patents, Royalties, Other Intellectual Property: Dr Sworder is an inventor on a patent related to new cell-free DNA based methods for characterizing mechanisms of resistance to CAR T-cells, Dr Sworder is an inventor on patents related to new methods for treating conditions or optimizing therapeutic efficacy of CAR T-cells. Hua-Jay J. Cherng . Honoraria: ADC Therapeutics. Travel, Accommodations, Expenses: ADC Therapeutics. Christian Kuffer . Employment: MorphoSys. Patents, Royalties, Other Intellectual Property: Anti-CD19 therapy in patients having a limited number of NK cells (US20220242952A1). Derek Blair . Employment: MorphoSys. Stock and Other Ownership Interests: Bristol Myers Squibb. Krystal Brown . Employment: Myriad Genetics, Adela, Foresight Diagnostics, GeneDx/BioReference. Jordan S. Goldstein . Consulting or Advisory Role: AstraZeneca. Andre Schultz . Employment: Foresight Diagnostics, Fate Therapeutics (I). Sandra Close . Employment: Foresight Diagnostics. Leadership: Foresight Diagnostics. Stock and Other Ownership Interests: Foresight Diagnostics. Jacob J. Chabon . Employment: Foresight Diagnostics. Leadership: Foresight Diagnostics. Stock and Other Ownership Interests: Foresight Diagnostics. Patents, Royalties, Other Intellectual Property: Cancer Biomarkers. Maximilian Diehn . Leadership: Foresight Diagnostics. Stock and Other Ownership Interests: CiberMed, Foresight Diagnostics, Perception Medicine. Consulting or Advisory Role: AstraZeneca, Regeneron, Foresight Diagnostics, CiberMed, Perception Medicine, Gritstone Bio. Research Funding: AstraZeneca (Inst). Patents, Royalties, Other Intellectual Property: Patent filings on ctDNA detection assigned to Stanford University (Inst), Patent filings on tumor treatment resistance mechanisms assigned to Stanford University (Inst), Royalties from Roche for patent licensing fees, Royalties from Foresight Diagnostics for patent licensing fees. Travel, Accommodations, Expenses: Foresight Diagnostics, Regeneron. Open Payments Link: https://openpaymentsdata.cms.gov/physician/937688. Ash A. Alizadeh . Leadership: Lymphoma Research Foundation, Foresight Diagnostics, Resero Bio. Stock and Other Ownership Interests: CiberMed, CAPP Medical, Foresight Diagnostics, CARGO Therapeutics, Resero Bio, Gilead Sciences, Gilead/Forty Seven. Honoraria: Roche, Janssen Oncology. Consulting or Advisory Role: Celgene, Roche/Genentech, Gilead Sciences, CiberMed, Foresight Diagnostics, Arima Genomics, Adaptive Biotechnologies. Research Funding: Celgene, Bristol Myers Squibb/Celgene/Juno. Patents, Royalties, Other Intellectual Property: Patent filings on ctDNA detection, assigned to Stanford University (Inst), Royalties from Foresight Diagnostics for patent licensing fees, Patent filings on tumor and tissue deconvolution methods assigned to Stanford University (Inst), Royalties from Roche for patent licensing fees. Travel, Accommodations, Expenses: Roche, Gilead Sciences, Foresight Diagnostics. Open Payments Link: https://openpaymentsdata.cms.gov/physician/598302. No other potential conflicts of interest were reported.
PMID 40802906 · 2025The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study.
Declarations. Ethics approval: This survey was conducted in compliance with the Ministerial Ordinance on Post-Marketing Surveillance and Testing of Drugs (GPSP) in Japan (Ministry of Health, Labour and Welfare Ordinance No. 171 dated December 20, 2004) upon approval of the heads of each institution. All institutions that provided the data agreed for the survey results to be published. Informed consent: A post-marketing surveillance study is exempt from obtaining informed consent by the ordinance. Competing interests: NS received consulting fees for serving on the advisory board from Kyowa Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd.; honoraria from Kyowa Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Merck Biopharma Co., Ltd., and Bristol-Myers Squibb K.K.; and research funding from Daiichi Sankyo Co., Ltd. MSD K.K., and AstraZeneca K.K. SS received lecture fees from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Novartis Pharma K.K., Eisai Co., Ltd., Takeda Pharmaceutical Company Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., AstraZeneca K.K., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Gilead Sciences, Inc., Exact Sciences K.K. and research grants from Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., MSD K.K., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc., Eli Lilly Japan K.K., Sanofi K.K.; had an advisory role for Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K.; and was an executive board member of JBCRG (Japan Breast Cancer Research Group), JBCS (Japan Breast Cancer Society), JSMO (Japanese Society of Medical Oncology) and BIG (Breast International Group). HK, TY, and MI are employees of Kyowa Kirin Co., Ltd.
PMID 41273402 · 2025Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression-Free Survival in Diffuse Large B-Cell Lymphoma.
Outi Kuittinen, Research grant: Incyte. Consultation fees: Sobi, Janssen, Abbvie. Advisory board membership: Abbvie, Serb SA, Roche.
PMID 41275414 · 2025Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.
Conflict-of-interest disclosure: F.V. reports research funding from and/or honoraria for service as a consultant from Allogene, Caribou, Ambos (Spain), and Geron Corporation. T.M.H. reports honoraria for service on the data monitoring committee from Eli Lilly and as a consultant from Genmab and Genentech. The remaining authors declare no competing financial interests.
PMID 41707114 · 2026Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group.
Disclosure statement Disclosure of potential conflict of interest: J. Calvão has received honoraria and/or travel support from Kyowa Kirin, LEO, and Adcetris. C. Jonak has received consulting and/or lecture fees and/or travel support from Almirall, Kyowa Kirin, Recordati Rare Diseases, Stemline Therapeutics, and Takeda. J. P. Nicolay has received travel and congress participation funding by TEVA and Novartis; and consulting from TEVA, Almirall, Biogen, Novartis, Kyowa Kirin, Innate Pharma, Takeda, Actelion, Therakos, Pierre Fabre, UCB Pharma, and Recordati. M. Battistella has received honoraria and/or travel support from Kyowa Kirin, Innate Pharma, Takeda, Recordati, BMS, MSD, Regeneron, and Sanofi. W. Kempf has received honoraria and/or travel support from Stemline and Recordati. P. L. Ortiz-Romero has received honoraria from Kyowa Kirin, Takeda, Helsinn, Recordati Rare Diseases, and Mallinckrodt. P. Brunner has received personal fees from Almirall, Sanofi, Janssen, LEO Pharma, AbbVie, Pfizer, Boehringer Ingelheim, GSK, Regeneron, Eli Lilly, Celgene, Novartis, UCB, Merck, RAPT Therapeutics, Galderma, Immunocore, TD Securities, Apogee and Bristol Myers Squibb; P. Brunner has received research support from Pfizer (grant paid to his institution) and is an investigator for Pfizer and Abbvie. M. Gonçalo has received honoraria and/or served on advisory boards for AbbVie, Almirall, Astra-Zeneca, Janssen, LEO Pharma, Pfizer, Sanofi, Novartis, Biocryst, and Takeda; and reports service as secretary-general of European Academy of Dermatology and Venereology (EADV). E. Guenova is a member of the EADV and the European Organization for Research and Treatment of Cancer; and holds stock in Scailyte AG. The rest of the authors declare that they have no relevant conflicts of interest.
PMID 41967816 · 2026Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.
Conflict of Interest Disclosures: Dr Xu reported holding issued patents CN201910228406.8, TW108141826, EP19887480.2, US17/295,494, JP2021-551329, KR10-2021-7018968, AU2019385373, CA3120207, RU2021114295, PH1-2021-551138, MYPI2021002751, and HK62022045863.7 and having pending patents CN202311474046.2, PCT/CN2019/119170, BR112021009627-2, IDP00202104645, and SG11202105137R. Dr J. Zhu reported receiving funding from ShenZhen Chipscreen Biosciences Co Ltd during the conduct of the study. Dr W. Zhao reported holding issued patents CN201910228406.8, TW108141826, EP19887480.2, US17/295,494, JP2021-551329, KR10-2021-7018968, AU2019385373, CA3120207, RU2021114295, PH1-2021-551138, MYPI2021002751, and HK62022045863.7; having pending patents CN202311474046.2, PCT/CN2019/119170, BR112021009627-2, IDP00202104645, and SG11202105137R; and receiving funding from ShenZhen Chipscreen Biosciences Co Ltd during the conduct of the study.
PMID 42018318 · 2026MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma.
T.C. Burns reports nonfinancial support and other support from Predicine, nonfinancial support from John Hopkins Pediatric Radiation Oncology Research Center, Gibson Oncology, Aminex Therapeutics, Integra, Medtronic, Foundation Medicine, Elios Therapeutics, Orbus Therapeutics, and Joanneum Research, other support from Servier, grants from the NIH, Focused Ultrasound Foundation, Brains Together for a Cure, Humor to Fight the Tumor, SonALAsense, Tumor Research Alliance, Brain Cancer Research Alliance, and Carthera, and grants and nonfinancial support from Alpheus Medical, outside the submitted work, as well as a patent for Drug Delivery and Biomarker Access Devices licensed. U. Farooq reports personal fees from Kite Pharma outside the submitted work. T.M. Habermann reports grants from NIH during the conduct of the study. B.J. Erickson reports grants from NIH during the conduct of the study. W.O. Tobin reports grants from NIH during the conduct of the study; grants from Merck outside the submitted work; and royalties from Oxford University Press. J.E. Eckel-Passow reports grants from NIH during the conduct of the study. No disclosures were reported by the other authors.
PMID 42081255 · 2026Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis.
Disclosure Ari R. Pelcovits reports research funding from Brown University Advanced CTR Pilot Projects Grant, Indapta Therapeutics, AbbVie, and ADC Therapeutics. He is additionally on the advisory board of Avencell. Alexander M. Gorzewski, Christina Raker, Victoria A. Gill, Thomas Palladino, and Sai P. Kota have no disclosures.
PMID 42177127 · 202601
Current Standard-of-Care Sources
Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.
[China lymphoma diagnosis and treatment guideline (2026 edition)].
Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026
PMID 41876194European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.
The British journal of dermatology · 2025
PMID 40795052Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
PMID 41031482Large B-cell lymphoma: The LYSA pragmatic guidelines.
European journal of cancer (Oxford, England : 1990) · 2026
PMID 41352004SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
PMID 41129029Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025.
The Journal of dermatology · 2025
PMID 41204060Modern approaches to radiotherapy in primary cutaneous lymphomas: insights and recommendations from the DEGRO dermato-oncology working group.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
PMID 40924120Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee.
Bone marrow transplantation · 2025
PMID 41034407Radiotherapy for haematological malignancies: Current best practices and advancements.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025
PMID 41106036A practical approach to panel design, validation, and interpretation for the evaluation of T-cell neoplasms by flow cytometry.
Cytometry. Part B, Clinical cytometry · 2025
PMID 41122063[The guideline for the diagnosis and treatment of marginal zone lymphoma in China (2025)].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
PMID 41339040NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025
PMID 4106727702
Highest-Priority Research
[China lymphoma diagnosis and treatment guideline (2026 edition)].
Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026
Lymphoma is one of the most common malignancies in China. Lymphoma exhibited complex pathological subtypes with significant heterogeneity, the treatment strategies varied. In recent years, with a deeper understanding of the mechanisms of oncogenesis and disease progression of lymphoma, significant development has been made in diagnosis and treatment, leading to the improvement of patients' clinical outcomes. In order to update the progress in the diagnosis and treatment of lymphoma. The Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care, the China Anti-cancer Association Lymphoma Committee, and the Chinese Association for Clinical On…
PMID 41876194European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.
The British journal of dermatology · 2025
In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma/LPD (PCMZL/LPD). The latter is still classified as primary cutaneous marginal zone lymphoma (PCMZL) in the 5th edition of the World Health Organization classification. A survey was previously carried out among 30 cutaneous lymphoma centres on the effects of this new terminology on clinical management. The results revealed considerable heterogeneity and emphasized the need to develop uniform recommendations…
PMID 40795052Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-…
PMID 41031482Large B-cell lymphoma: The LYSA pragmatic guidelines.
European journal of cancer (Oxford, England : 1990) · 2026
The management of large B-cell lymphomas (LBCL) has undergone major changes over the last 5 years. These changes reflect the availability of new therapies (immunotherapies, cell therapies, targeted molecules), but also a better compartmentalization of the entities and their specific clinical characteristics. Numerous first-, second- and third-line therapeutic strategies are available, and each practitioner is committed to selecting the treatment that offers the best balance between efficacy and toxicity. Advances in the understanding of LBCL biology, coupled with improvements in diagnostic and monitoring tools and therapeutic approaches, have significantly enhanced patient outcomes in recent…
PMID 41352004SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
Diffuse large B-cell lymphoma (DLBCL) is the most frequent histological subtype of non-Hodgkin lymphoma and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hematopathologist is recommended to establish the diagnosis. Twenty years following its introduction, the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains the standard first-line treatment. No modification of this scheme (increased chemotherapy dose intensity, new monoclonal antibodies, or the addition of immunomodulators or anti-target agents) has significantly improved the clinical outcomes, whereas ther…
PMID 41129029Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025.
The Journal of dermatology · 2025
Since the publication of the Japanese guidelines for the management of cutaneous lymphomas in 2020, the WHO classification of hematolymphoid neoplasms has been updated, and a number of novel systemic drugs for cutaneous T-cell lymphoma have been approved in Japan. In 2025, we revised the Japanese guidelines for the management of cutaneous lymphomas in consideration of recent advances in our understanding of the pathophysiology and classification of cutaneous lymphomas, together with the update in treatment strategies reflecting the advent of novel drugs. This revision was also conducted under the Japanese Dermatological Association's commission, incorporating expert reviews and public commen…
PMID 41204060Modern approaches to radiotherapy in primary cutaneous lymphomas: insights and recommendations from the DEGRO dermato-oncology working group.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
The growing use of reduced-dose radiotherapy in patients with primary cutaneous lymphoma is a promising development. Nevertheless, the absence of controlled clinical trials to ascertain standardized doses for each specific type constitutes a significant impediment to the advancement of this field. This expert opinion strongly advocates for advancements in radiation oncology practice that address the unique complexities of primary cutaneous lymphoma. By refining our methodologies, we can optimize patient care and outcomes in this dynamic field.
PMID 40924120Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee.
Bone marrow transplantation · 2025
This manuscript provides expert recommendations on the role of allogeneic hematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically Mycosis Fungoides (MF) and Sezary Syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and hematologists. These recommendations aim to harmonise clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-HC…
PMID 41034407Radiotherapy for haematological malignancies: Current best practices and advancements.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025
Haematological malignancies include a broad spectrum of diseases. The substantial progress made in systemic treatment over the last 20years is reshaping the role of radiotherapy. Recent technological progress in imaging and radiotherapy has led to significant refinements in targets definition, sparing of organ at risk to reduce toxicity, thus ensuring that radiotherapy remains the cornerstone for several indications. We present the recommendations of the Société française de radiothérapie oncologique for radiotherapy of haematological malignancies, which continues to evolve rapidly in terms of therapeutic strategy.
PMID 41106036A practical approach to panel design, validation, and interpretation for the evaluation of T-cell neoplasms by flow cytometry.
Cytometry. Part B, Clinical cytometry · 2025
The diagnosis of T-cell neoplasms remains one of the most challenging areas in hematopathology due to the immunophenotypic heterogeneity and subtle aberrancies often present in these entities. This "Best Practice" manuscript provides a practical framework for laboratories to design, validate, and interpret immunophenotyping studies of immature and mature T-cell neoplasms. We outline the utility of key antigens in the screening and classification of T-cell lymphomas/leukemia including TRBC1 and TRBC2. Analytical strategies using the "difference from normal" method and template-based gating are discussed, along with validation considerations aligned with CLSI H62 guidelines. By integrating the…
PMID 41122063[The guideline for the diagnosis and treatment of marginal zone lymphoma in China (2025)].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
Marginal zone lymphoma (MZL) is an indolent B-cell lymphoma arising from marginal zone B cells within lymphoid follicles, accounting for approximately 5%-15% of non-Hodgkin lymphomas. MZL is characterized by diagnostic challenges and diverse treatment options, making it a challenging subtype in clinical practice. In recent years, with the rapid progress in lymphoma research, the understanding of MZL has improved significantly worldwide. To further standardize the diagnosis and treatment of MZL in China, the Chinese Workshop of Indolent Lymphomas convened a panel of national experts. Based on thorough discussion and consensus, this guideline was developed to provide a reference for medical pr…
PMID 41339040NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025
The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody-drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor-based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN …
PMID 4106727703
Latest Research — Last 24 Months
2026
2026
2026
Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.
Journal of the European Academy of Dermatology and Venereology : JEADV · PMID 41821352
2026
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
Journal of medical economics · PMID 42452801
2026
The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.
Clinical lymphoma, myeloma & leukemia · PMID 42409674
2026
[Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · PMID 42409743
2026
Attributable Fraction of Epstein-Barr Virus in Subtypes of Lymphoma: A Systematic Review and Global Meta-Analysis.
International journal of cancer · PMID 41947331
2026
2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
The New England journal of medicine · PMID 42341302
2026
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.
American journal of hematology · PMID 42240061
2026
The surgery for the patients with intestinal non‑Hodgkin lymphomas: a nationwide study.
Annals of medicine · PMID 41732903
2026
2026
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
Oncoimmunology · PMID 42415230
2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.
Nature communications · PMID 42297808
2026
Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · PMID 41764665
04
Treatment Options Studied in the PubMed Collection
These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.
moderate-confidence evidence
rituximab
40 linked PMIDs20632 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, response rate, adverse events, complete response, reported clinical outcomes, progression-free survival, recurrence, event-free survival
- Populations represented
- diffuse large B-cell lymphoma; general population; diffuse large B-cell lymphoma; first-line; CD20; diffuse large B-cell lymphoma; CD20; diffuse large B-cell lymphoma; first-line; older adults
- Mechanism
- BACKGROUND: This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma
preliminary evidence
Receptors, Chimeric Antigen
24 linked PMIDs6526 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- response rate, overall survival, progression-free survival, adverse events, complete response, reported clinical outcomes, quality of life, cytokine release syndrome
- Populations represented
- CD20; CD19; general population; diffuse large B-cell lymphoma; CD19; follicular lymphoma; CD19; children
- Mechanism
- Axi-cel plus rituximab treatment led to durable responses with no new safety signals despite persistent B cell aplasia and pharmacokinetics of axi-cel were unaffected, indicating that dual targeting of CD19 and CD20 is a feasible and safe approach to potentially limit antigen escape Mechanistically, the model revealed that CMV reactivation was associated with reduced peak CAR-T expansion by 41.8 % ( p < 0.001 ) in counterfactual analysis
moderate-confidence evidence
Cyclophosphamide
16 linked PMIDs1571 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- recurrence, overall survival, progression-free survival, complete response, adverse events, reported clinical outcomes
- Populations represented
- diffuse large B-cell lymphoma; first-line; diffuse large B-cell lymphoma; general population; follicular lymphoma; advanced; first-line; CD20; diffuse large B-cell lymphoma; first-line; older adults; diffuse large B-cell lymphoma; CD20
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Biomarkers, Tumor
16 linked PMIDs1530 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival
- Populations represented
- diffuse large B-cell lymphoma; diffuse large B-cell lymphoma; first-line; diffuse large B-cell lymphoma; follicular lymphoma; general population; diffuse large B-cell lymphoma; MYC; BCL2; BCL6
- Mechanism
- Immune checkpoints are key regulators of tumor-immune interactions and important targets in cancer therapy These findings demonstrate that ferroptosis regulates DLBCL progression and identify potential biomarkers/therapeutic targets requiring validation to develop new therapies
moderate-confidence evidence
Doxorubicin
15 linked PMIDs1532 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- recurrence, overall survival, progression-free survival, complete response, adverse events, reported clinical outcomes
- Populations represented
- diffuse large B-cell lymphoma; first-line; diffuse large B-cell lymphoma; general population; follicular lymphoma; advanced; first-line; CD20; diffuse large B-cell lymphoma; first-line; older adults; diffuse large B-cell lymphoma; CD20
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
Prednisone
13 linked PMIDs1124 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- recurrence, overall survival, complete response, progression-free survival, adverse events, reported clinical outcomes
- Populations represented
- diffuse large B-cell lymphoma; first-line; general population; diffuse large B-cell lymphoma; follicular lymphoma; advanced; first-line; CD20; diffuse large B-cell lymphoma; first-line; older adults; diffuse large B-cell lymphoma; CD20
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
Vincristine
13 linked PMIDs840 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- recurrence, overall survival, complete response, progression-free survival, adverse events, reported clinical outcomes
- Populations represented
- diffuse large B-cell lymphoma; first-line; general population; diffuse large B-cell lymphoma; follicular lymphoma; advanced; first-line; CD20; diffuse large B-cell lymphoma; first-line; older adults; follicular lymphoma
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
CAR T-cell therapy
12 linked PMIDs6296 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, progression-free survival, adverse events, complete response, cytokine release syndrome, response rate
- Populations represented
- diffuse large B-cell lymphoma; general population; diffuse large B-cell lymphoma; CD19; CD20; CD19; CD19; CD19; children
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Antibodies, Monoclonal, Humanized
12 linked PMIDs1530 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, complete response, overall survival, progression-free survival, cytokine release syndrome, response rate, quality of life, objective response rate
- Populations represented
- diffuse large B-cell lymphoma; CD19; follicular lymphoma; general population; follicular lymphoma; early-stage; stage I; CD20; BCL2; diffuse large B-cell lymphoma
- Mechanism
- Loncastuximab tesirine (Lonca), an antibody conjugate targeting CD19, has demonstrated significant clinical benefit in R/R DLBCL in a global phase II LOTIS-2 study We conducted a phase 1b study evaluating safety and tolerability of tafasitamab, a CD19-targeting immunotherapy, in Japanese patients with B-cell non-Hodgkin lymphoma (NHL)
moderate-confidence evidence
R-CHOP
11 linked PMIDs1534 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, progression-free survival, adverse events, complete response, event-free survival, objective response rate, response rate
- Populations represented
- diffuse large B-cell lymphoma; follicular lymphoma; advanced; first-line; CD20; diffuse large B-cell lymphoma; CD20; follicular lymphoma; diffuse large B-cell lymphoma; first-line; CD20; diffuse large B-cell lymphoma; advanced; stage IV
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Antibodies, Bispecific
9 linked PMIDs6930 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, cytokine release syndrome, reported clinical outcomes, overall survival, mortality
- Populations represented
- follicular lymphoma; CD20; general population; CD19
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Fluorodeoxyglucose F18
9 linked PMIDs1787 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, progression-free survival, complete response, overall survival, response rate
- Populations represented
- diffuse large B-cell lymphoma; general population; follicular lymphoma; second-line; follicular lymphoma; stage II; stage III; CD20
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Antigens, CD19
9 linked PMIDs294 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- response rate, adverse events, progression-free survival, overall survival, complete response, cytokine release syndrome
- Populations represented
- CD20; CD19; CD19; CD19; children
- Mechanism
- Axi-cel plus rituximab treatment led to durable responses with no new safety signals despite persistent B cell aplasia and pharmacokinetics of axi-cel were unaffected, indicating that dual targeting of CD19 and CD20 is a feasible and safe approach to potentially limit antigen escape
preliminary evidence
Antigens, CD20
8 linked PMIDs194 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- progression-free survival, response rate, adverse events, overall survival, complete response, reported clinical outcomes, cytokine release syndrome
- Populations represented
- CD20; CD19; CD20
- Mechanism
- Although CD20 targeting has improved outcomes in humans with non-Hodgkin's lymphoma, it remains challenging in dogs because of the lack of effective anti-CD20 antibodies Here, we describe PSB202, a first-in-class bifunctional antibody co-targeting CD20 and CD37 to deplete malignant B cells independently of T-cell engagement
preliminary evidence
bendamustine
7 linked PMIDs15588 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, progression-free survival, response rate, adverse events, complete response, reported clinical outcomes
- Populations represented
- general population; follicular lymphoma; advanced; follicular lymphoma; second-line; diffuse large B-cell lymphoma; follicular lymphoma; mantle cell lymphoma; diffuse large B-cell lymphoma; second-line
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Antineoplastic Agents, Immunological
7 linked PMIDs2469 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, overall survival, progression-free survival, complete response, reported clinical outcomes, response rate
- Populations represented
- general population; diffuse large B-cell lymphoma; CD20; CD20; diffuse large B-cell lymphoma; CD19
- Mechanism
- BACKGROUND: Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 epitopes, was shown to induce potent tumor cell killing through enhanced complement-dependent cytotoxicity (CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo
moderate-confidence evidence
Antibodies, Monoclonal, Murine-Derived
6 linked PMIDs658 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, progression-free survival, complete response, adverse events
- Populations represented
- diffuse large B-cell lymphoma; follicular lymphoma; advanced; first-line; CD20; follicular lymphoma; advanced; follicular lymphoma; first-line
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Lenalidomide
6 linked PMIDs450 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- objective response rate, response rate, overall survival, progression-free survival, complete response, reported clinical outcomes, adverse events, cytokine release syndrome
- Populations represented
- general population; mantle cell lymphoma; follicular lymphoma; advanced; follicular lymphoma
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
05
Conflicting Research
higher-confidence evidence
11 studiesReceptors, Chimeric Antigen · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 9benefit: 1harm: 1
higher-confidence evidence
9 studiesPrednisone · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 7null: 1benefit: 1
higher-confidence evidence
9 studiesCyclophosphamide · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 6null: 2benefit: 1
higher-confidence evidence
9 studiesVincristine · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 7null: 1benefit: 1
higher-confidence evidence
7 studiesRituximab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: diffuse large B-cell lymphoma; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
benefit: 1unknown: 5null: 1
moderate-confidence evidence
7 studiesFluorodeoxyglucose F18 · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 4benefit: 2harm: 1
higher-confidence evidence
7 studiesDoxorubicin · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 5null: 1benefit: 1
moderate-confidence evidence
5 studiesAntigens, CD20 · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: CD20. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 4mixed: 1
preliminary evidence
4 studiesAntibodies, Bispecific · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: CD20. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 3mixed: 1
moderate-confidence evidence
4 studiesR-CHOP · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: diffuse large B-cell lymphoma; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
benefit: 1unknown: 2null: 1
moderate-confidence evidence
2 studiesFluorodeoxyglucose F18 · reported clinical outcomes
Status: apparently conflicting; different clinical questions. Population: CD20. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 1mixed: 1
preliminary evidence
2 studiesCD3 Complex · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: CD20. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 1mixed: 1
06
Failed or Negative Trials
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.
randomized controlled trial · 2026 · PMID 41260259
Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.
randomized controlled trial · 2025 · PMID 40397196
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
randomized controlled trial · 2024 · PMID 38267866
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.
randomized controlled trial · 2025 · PMID 41335575
Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.
randomized controlled trial · 2025 · PMID 40829107
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.
randomized controlled trial · 2022 · PMID 35858181
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.
randomized controlled trial · 2026 · PMID 41746629
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
randomized controlled trial · 2024 · PMID 37996986
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
randomized controlled trial · 2025 · PMID 40499012
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.
randomized controlled trial · 2024 · PMID 39376156
07
Emerging and Experimental Research
Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.
meta analysis · 2026 · PMID 42069410
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.
randomized controlled trial · 2026 · PMID 41260259
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
randomized controlled trial · 2026 · PMID 42134356
Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.
randomized controlled trial · 2026 · PMID 41989666
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.
randomized controlled trial · 2026 · PMID 42285113
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.
randomized controlled trial · 2026 · PMID 42283231
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
randomized controlled trial · 2026 · PMID 42341302
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.
phase 1 clinical trial · 2026 · PMID 42463852
Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study.
phase 2 clinical trial · 2026 · PMID 42496861
Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.
phase 1 clinical trial · 2026 · PMID 42490071
08
Evidence Gaps
Detailed risk-of-bias assessment remains limited
PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care60 records
Rank112.0
European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.
The British journal of dermatology · 2025 · PMID 40795052
In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma/LPD (PCMZL/LPD). The latter is still classified as primary cutaneous marginal zone lymphoma (PCMZL) in the 5th edition of the World Health Organization classification. A survey was previously carried out among 30 cutaneous lympho…
Rank112.0
[China lymphoma diagnosis and treatment guideline (2026 edition)].
Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 41876194
Lymphoma is one of the most common malignancies in China. Lymphoma exhibited complex pathological subtypes with significant heterogeneity, the treatment strategies varied. In recent years, with a deeper understanding of the mechanisms of oncogenesis and disease progression of lymphoma, significant development has been made in diagnosis and treatment, leading to the improvement of patients' clinical outcomes. In order to update the progress in the diagnosis and treatment of lymphoma. The Medical Oncology Branch of C…
Rank110.0
SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 41129029
Diffuse large B-cell lymphoma (DLBCL) is the most frequent histological subtype of non-Hodgkin lymphoma and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hematopathologist is recommended to establish the diagnosis. Twenty years following its introduction, the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains the standard first-line treatment. No modification of this scheme (increas…
Rank110.0
Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025.
The Journal of dermatology · 2025 · PMID 41204060
Since the publication of the Japanese guidelines for the management of cutaneous lymphomas in 2020, the WHO classification of hematolymphoid neoplasms has been updated, and a number of novel systemic drugs for cutaneous T-cell lymphoma have been approved in Japan. In 2025, we revised the Japanese guidelines for the management of cutaneous lymphomas in consideration of recent advances in our understanding of the pathophysiology and classification of cutaneous lymphomas, together with the update in treatment strategi…
Rank110.0
A practical approach to panel design, validation, and interpretation for the evaluation of T-cell neoplasms by flow cytometry.
Cytometry. Part B, Clinical cytometry · 2025 · PMID 41122063
The diagnosis of T-cell neoplasms remains one of the most challenging areas in hematopathology due to the immunophenotypic heterogeneity and subtle aberrancies often present in these entities. This "Best Practice" manuscript provides a practical framework for laboratories to design, validate, and interpret immunophenotyping studies of immature and mature T-cell neoplasms. We outline the utility of key antigens in the screening and classification of T-cell lymphomas/leukemia including TRBC1 and TRBC2. Analytical str…
Rank110.0
Modern approaches to radiotherapy in primary cutaneous lymphomas: insights and recommendations from the DEGRO dermato-oncology working group.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025 · PMID 40924120
The growing use of reduced-dose radiotherapy in patients with primary cutaneous lymphoma is a promising development. Nevertheless, the absence of controlled clinical trials to ascertain standardized doses for each specific type constitutes a significant impediment to the advancement of this field. This expert opinion strongly advocates for advancements in radiation oncology practice that address the unique complexities of primary cutaneous lymphoma. By refining our methodologies, we can optimize patient care and ou…
Rank110.0
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · PMID 41067277
The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody-drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor-based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest t…
Rank110.0
Radiotherapy for haematological malignancies: Current best practices and advancements.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025 · PMID 41106036
Haematological malignancies include a broad spectrum of diseases. The substantial progress made in systemic treatment over the last 20years is reshaping the role of radiotherapy. Recent technological progress in imaging and radiotherapy has led to significant refinements in targets definition, sparing of organ at risk to reduce toxicity, thus ensuring that radiotherapy remains the cornerstone for several indications. We present the recommendations of the Société française de radiothérapie oncologique for radiothera…
Rank110.0
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41031482
This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists…
Rank110.0
Large B-cell lymphoma: The LYSA pragmatic guidelines.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41352004
The management of large B-cell lymphomas (LBCL) has undergone major changes over the last 5 years. These changes reflect the availability of new therapies (immunotherapies, cell therapies, targeted molecules), but also a better compartmentalization of the entities and their specific clinical characteristics. Numerous first-, second- and third-line therapeutic strategies are available, and each practitioner is committed to selecting the treatment that offers the best balance between efficacy and toxicity. Advances i…
Rank110.0
[The guideline for the diagnosis and treatment of marginal zone lymphoma in China (2025)].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025 · PMID 41339040
Marginal zone lymphoma (MZL) is an indolent B-cell lymphoma arising from marginal zone B cells within lymphoid follicles, accounting for approximately 5%-15% of non-Hodgkin lymphomas. MZL is characterized by diagnostic challenges and diverse treatment options, making it a challenging subtype in clinical practice. In recent years, with the rapid progress in lymphoma research, the understanding of MZL has improved significantly worldwide. To further standardize the diagnosis and treatment of MZL in China, the Chinese…
Rank110.0
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee.
Bone marrow transplantation · 2025 · PMID 41034407
This manuscript provides expert recommendations on the role of allogeneic hematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically Mycosis Fungoides (MF) and Sezary Syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and hematologists. …
Rank105.5
Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352
INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …
Rank100.0
Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma.
Blood cancer journal · 2025 · PMID 41461632
There is currently no clear consensus on the standard of care for relapsed or refractory follicular lymphoma (FL) beyond third-line therapy, where both anti-CD19 CAR-T-cell therapy (CAR-T) and CD3×CD20 bispecific antibodies (BsAbs) have demonstrated efficacy. This study aimed to examine their efficacy and toxicity profiles. Relevant studies published between January 2010 and June 2025 were identified through major databases. Of 3960 records screened, 12 studies met the inclusion criteria-7 involving CAR-T and 5 inv…
Rank100.0
Adiposity and cancer: systematic review and meta-analysis.
Nature metabolism · 2026 · PMID 42297908
Obesity is a major health challenge. Here we show that body mass index is positively associated with risk of 19 cancers and inversely associated with 3, based on a systematic review and meta-analysis of prospective studies of 25 cancer types. We searched PubMed, EMBASE and Scopus through to 23 April 2025, identifying 226 articles comprising 1.5 million incident cancers. We identified positive associations for leukaemia, non-Hodgkin lymphoma, bladder cancer and glioma, not previously identified by major consensus re…
Rank100.0
Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review.
Journal of comparative effectiveness research · 2026 · PMID 42359923
Aim: Several CAR-T cell therapies have received regulatory approval from both the US FDA and the EMA for the treatment of large B-cell lymphoma. However, direct comparative trials between CAR-T cell therapies are lacking, mainly due to different clinical development timelines and availabilities as well as substantial resource requirements and difficulties in recruiting sufficiently large and homogeneous cohorts from a highly pre-treated patient population. Consequently, indirect treatment comparisons (ITCs) play a …
Rank98.0
Protocol for a mixed-methods modified Delphi study for the development of a core domain set to assess the health-related quality of life of patients with mycosis fungoides and Sézary syndrome in clinical trials.
BMJ open · 2026 · PMID 41651511
INTRODUCTION: Cutaneous T cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas that primarily affects the skin and can mimic inflammatory dermatoses. Unlike many skin diseases, CTCL can lead to disabling symptoms, and advanced CTCL can even be fatal. Early studies investigating health-related quality of life (HRQOL) in patients with mycosis fungoides (MF) and Sézary syndrome (SS), common subtypes of CTCL, demonstrated significant impairment across numerous domains. The aim of this current study is to develop a …
Rank85.0
Current status of hematopoietic cell transplantation in patients with peripheral T-cell lymphoma including adult T-cell leukemia-lymphoma.
International journal of hematology · 2026 · PMID 41283963
Peripheral T-cell lymphomas (PTCLs) are biologically diverse and clinically aggressive, and are difficult to control long-term with conventional immunochemotherapy. Hematopoietic cell transplantation (HCT) is a key treatment option. Autologous HCT (auto-HCT) as first-line consolidation has shown durable progression-free survival in phase 2 studies and in the auto-HCT arm of the randomized AATT trial (intent-to-treat PFS 30-49%), although its routine use after complete metabolic response remains controversial. A pha…
Rank54.2
Validation of US Consensus Eligibility Criteria for Front-Line DLBCL Trials.
European journal of haematology · 2026 · PMID 41360116
Identifying patients eligible for front-line clinical trials with diffuse large B-cell lymphoma (DLBCL) has been challenging, primarily due to increasingly stringent inclusion criteria and the limitations of the International Prognostic Indices in identifying patients who are unlikely to achieve long-term remission after standard treatment. We aimed to assess the impact of using improved eligibility criteria established through a US-based Delphi-method survey to identify real-world DLBCL patients eligible for clini…
Rank53.1
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.
Blood · 2026 · PMID 41490516
Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic) relapse. SCNSL is a devastating event without therapeutic consensus. Thus, we aimed to evaluate treatment outcomes in an international cohort. Progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR, estimated using competing-risk models) were reported. Prognostic factors were identified in a 6-month land…
Rank52.6
Real-world lymphoma cohort in an HIV-endemic setting: cohort design, epidemiological features and impact of implementing novel classification standards.
BMC cancer · 2026 · PMID 41928152
BACKGROUND: Lymphoma real-world observational data and accurate diagnostic systems are lacking in low-resource HIV-endemic settings. We established a new lymphoma registry to generate internationally comparable, clinically validated data, with up-to-date disease classification. We also describe our findings on aggressive B-cell lymphoma. METHODS: The descriptive retrospective cohort included patients ≥ 13 years of age newly diagnosed with lymphoma from 2005 to 2020. Patients were enrolled at a single site in a regi…
Rank52.5
Radiation Therapy Utilization for Primary Cutaneous T-Cell Lymphoma Is Lowest Among Patients Living in the Most Geographically Accessible Areas: An Australian Study.
International journal of radiation oncology, biology, physics · 2025 · PMID 40664276
PURPOSE: Cutaneous T-cell lymphomas (CTCL) are rare with increasing incidence. Most patients have skin-confined mycosis fungoides: a typically indolent, highly morbid, incurable disease requiring multi-lined treatment. For these patients, radiation therapy (RT) is efficacious, well-tolerated, and cost-effective; total skin electron beam therapy (TSEBT) is a specialized technique with proven quality-of-life benefits. Consensus on optimal treatment sequencing is lacking, creating heterogeneity in care. International …
Rank51.2
Apoptosis-related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma.
Hematology (Amsterdam, Netherlands) · 2026 · PMID 41635044
OBJECTIVES: Dysregulation of apoptosis-related genes (ARGs) may contribute to tumorigenesis and impact patient prognosis, but their specific influence on prognosis and immune characteristics in diffuse large B-cell lymphoma (DLBCL) remains unclear. METHODS: Gene expression profiles were collected from GEO datasets GSE10846 (training set; n = 414) and GSE181063 (validation set; n = 1310), totaling 1724 DLBCL samples. Univariate Cox and LASSO Cox regression analyses were performed to identified key ARGs, which were u…
Rank50.7
Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.
Blood · 2026 · PMID 41329859
Anaplastic large cell lymphomas (ALCLs) are CD30+ T-cell lymphomas that share pathologic features but differ in presentation, outcome, and genetics. Current classification incorporates clinical presentation and anaplastic lymphoma kinase (ALK) status but inadequately addresses molecular heterogeneity and therapeutic vulnerabilities. We studied 689 patients with ALCL in the LLMPP (Lymphoma/Leukemia Molecular Profiling Project) and performed expert consensus review, genetic subtyping (ALK, DUSP22, TP63, and triple ne…
Rank50.0
EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity.
Blood cancer journal · 2025 · PMID 41102158
EBV-positive polymorphic B-cell lymphoproliferative disorder, NOS (poly B-LPD), is a newly defined entity in the 2022 International Consensus Classification of mature lymphoid neoplasms. Its clinical behavior and optimal treatment approach remain poorly characterized. We conducted a retrospective study of 31 patients diagnosed with EBV+ poly B-LPD at Mayo Clinic (2003-2024), excluding transplant recipients. Median age was 56 years; 71% had extranodal involvement, 68% presented with stage III/IV disease, and 52% had…
Diagnosis And Screening84 records
Rank105.5
Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352
INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …
Rank105.1
The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42409674
The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the …
Rank103.0
[Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026 · PMID 42409743
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive type of intestinal T-cell lymphoma. With the application of high-throughput sequencing technologies in recent years, the understanding of this entity has become increasingly comprehensive. The World Health Organization classification of lymphoma now recognizes MEITL as a distinct disease entity. However, the extreme rarity of MEITL poses substantial challenges for clinical diagnosis and management, and patient outcomes re…
Rank103.0
Single-cell RNA sequencing unveils CD8+ T cell heterogeneity in the diffuse large B-cell lymphoma microenvironment: A systematic review.
Critical reviews in oncology/hematology · 2026 · PMID 42144172
BACKGROUND: The heterogeneous response to immunotherapy in diffuse large B-cell lymphoma (DLBCL) is largely attributable to the diverse functional states of CD8⁺ T cells within the tumor microenvironment. Although single-cell RNA sequencing (scRNA-seq) has revolutionized cellular resolution, a systematic synthesis of this evidence to map CD8⁺ T cell heterogeneity and its clinical implications in DLBCL is currently lacking. METHODS: Following the PRISMA guidelines and a PROSPERO-registered protocol (CRD420261282336)…
Rank94.9
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.
American journal of hematology · 2026 · PMID 42240061
One quarter of patients with diffuse large B-cell lymphoma (DLBCL) who achieve a complete response following front-line therapy will eventually experience disease relapse. Existing prognostic models use baseline factors to predict outcomes from the start of initial therapy and are not intended for use following completion of treatment. We developed a conditional event-free survival (cEFS) tool that predicts a patient's risk of lymphoma recurrence after completing front-line therapy taking into consideration baselin…
Rank79.5
TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.
International journal of hematology · 2026 · PMID 42262647
T follicular helper (TFH)-derived peripheral T-cell lymphomas (PTCLs) harbor frequent mutations in epigenetic regulators and are sensitive to epigenetic therapies. The histone deacetylase inhibitor tucidinostat demonstrated efficacy in relapsed/refractory PTCL, especially angioimmunoblastic T-cell lymphoma (AITL), in a phase IIb trial; however, the lack of TFH phenotyping has prevented assessment of the predictive value of this phenotype across a broader PTCL spectrum. Therefore, we retrospectively analyzed patient…
Rank77.0
A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.
Nature communications · 2026 · PMID 42527400
Chimeric antigen receptor (CAR) T-cell therapies are typically administered at high doses to maximize durable clinical responses. However, manufacturing constraints can limit the production of sufficient cells to achieve the intended dose. Although some patients experience durable responses after receiving lower CAR-T cell doses, the mechanisms underlying efficacy at these limited cell numbers remain poorly understood. To address this, we performed deep phenotyping of anti-CD19 CAR-T cell products and their corresp…
Rank75.0
Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.
Annals of medicine · 2026 · PMID 42482660
BACKGROUND: CD5-positive diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype with poor outcomes. Following the approval of Pola-R-CHP in China, this study aimed to evaluate its efficacy as initial therapy for this high-risk population. METHODS: We conducted a multicenter, retrospective study of previously untreated CD5-positive DLBCL patients who received Pola-R-CHP as first-line therapy between April 2023 and February 2025. Treatment response was assessed by PET/CT after 3 cycles and at the end of treat…
Rank74.2
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.
Leukemia & lymphoma · 2026 · PMID 41736495
To contextualize results from the single-arm ELM-2 study of odronextamab (CD20 × CD3 bispecific antibody) in relapsed/refractory (R/R) follicular lymphoma (FL) (N = 128), a post-hoc comparison was conducted versus third-line or later systemic therapies used in the real world (3L + RWST) in FLORA, a multinational, noninterventional study (N = 83; 100 lines of therapy). After weighting, objective response rate (80.5 vs. 52.7%; odds ratio [OR], 3.75 [95% CI, 1.98-7.11]), complete response rate (73.4 vs. 33.6%; OR, 5.3…
Rank73.5
Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.
European journal of nuclear medicine and molecular imaging · 2026 · PMID 42223630
PURPOSE: The clinical use of CD3-CD20-directed bispecific antibodies (BsAbs) has significantly improved outcomes of patients with relapsed/refractory LBCL. However, up to 50% of patients relapse. This study evaluated the prognostic value of longitudinal FDG-PET parameters. METHODS: 58 patients with baseline PET and 45 (78%) with first PET after BsAb initiation were included. Standard PET metrics and Deauville score (DS) were recorded, with percent changes at follow-up defined as ΔPET parameters. Prognostic impact o…
Rank72.9
Immunohistochemical Expression of p63 and GATA3 in Lymphomas of the Urinary Bladder: A Clinicopathologic Study of a Potential Diagnostic Pitfall.
International journal of surgical pathology · 2026 · PMID 41985039
Urinary bladder lymphomas are rare and may mimic urothelial carcinoma by morphology or unexpected expression of putative "urothelial" markers such as p63/ GATA3, the latter of which has not been thoroughly explored. Herein, we evaluate the clinicopathologic features of bladder lymphomas and assess the incidence of p63/GATA3 expression. A multi-institutional review identified 28 bladder lymphomas. Slides were re-reviewed for lymphoma subtype, growth pattern, urothelial colonization, and concurrent urothelial carcino…
Rank70.0
68 Ga-pentixafor PET/CT Indicates Inconsistent Response With Monoclonal Protein-based Response Criteria in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Patients Treated With Bruton Tyrosine Kinase Inhibitors.
Clinical nuclear medicine · 2026 · PMID 42113823
BACKGROUND: Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is a rare, indolent non-Hodgkin lymphoma. Bruton tyrosine kinase inhibitors (BTKis) have been widely used for the treatment of WM/LPL. The objective of this study is to evaluate the response assessed by 68 Ga-pentixafor PET/CT in patients with WM/LPL treated with either BTKi or chemoimmunotherapy. PATIENTS AND METHODS: This is a post hoc analysis of the data from our prospective cohort study. A total of 33 patients with newly diagnosed or…
Rank64.9
Clinicopathological and Imaging Distinction Between Ocular Adnexal MALT Lymphoma and IgG4-Related Ophthalmic Disease.
American journal of ophthalmology · 2026 · PMID 41985855
PURPOSE: To characterize clinicopathologic and imaging differences between ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) and IgG4-related ophthalmic disease (IgG4-ROD) and to evaluate clinical and artificial intelligence-assisted approaches for differentiating these entities. DESIGN: Retrospective, single-center observational cross-sectional study. PARTICIPANTS: Four hundred patients with pathologically confirmed orbital lymphoproliferative disease, including OAML (n = 287) and IgG4-ROD (n = 113)…
Rank54.2
Survival and prognostic features of early-stage diffuse large B-cell lymphoma in older adults.
Hematology (Amsterdam, Netherlands) · 2026 · PMID 41922932
BACKGROUND: Early-stage diffuse large B-cell lymphoma (ESDLBCL) in older adults is understudied, and existing prognostic tools such as the stage-adjusted International Prognostic Index (Sa-IPI) may not adequately account for comorbidity and age-related vulnerability. This study evaluated long-term outcomes and developed a simplified prognostic index for patients aged ≥ 60 years with ESDLBCL. METHODS: We retrospectively analyzed adults aged ≥ 60 years with stage I-II DLBCL treated at King Hussein Cancer Center betwe…
Rank52.6
Low Risk of Central Nervous System Relapse Among Patients With T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Despite High-Risk Disease Presentation.
European journal of haematology · 2026 · PMID 41974450
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of large B-cell lymphoma (LBCL) for which central nervous system (CNS) relapse remains a devastating complication. The CNS International Prognostic Index (IPI) is usually used to predict the risk of CNS relapse. However, the overall risk of CNS relapse among patients with THRLBCL remains poorly known. To clarify the risk of CNS relapse in THRLBCL, data for 106 patients with THRLBCL diagnosed between 2000 and 2020 were collected from seven hosp…
Rank51.2
Apoptosis-related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma.
Hematology (Amsterdam, Netherlands) · 2026 · PMID 41635044
OBJECTIVES: Dysregulation of apoptosis-related genes (ARGs) may contribute to tumorigenesis and impact patient prognosis, but their specific influence on prognosis and immune characteristics in diffuse large B-cell lymphoma (DLBCL) remains unclear. METHODS: Gene expression profiles were collected from GEO datasets GSE10846 (training set; n = 414) and GSE181063 (validation set; n = 1310), totaling 1724 DLBCL samples. Univariate Cox and LASSO Cox regression analyses were performed to identified key ARGs, which were u…
Rank50.9
Enhancing Diagnostic Precision in Malignant Hematological Disorders Through Risk Factor Analysis for High-Quality Bone Marrow Aspirate.
International journal of laboratory hematology · 2026 · PMID 41888063
BACKGROUND: Previous evidence suggests that the diagnostic role of bone marrow aspiration (BMA) is altered by the hematological malignancy itself, thereby reducing its diagnostic accuracy and potentially delaying patient care. This association, however, remains largely unevaluated. METHODS: We used a multivariable logistic regression model to estimate the association between hematological malignancies and the quality of the BMA, defined as optimal or suboptimal. Our primary outcome evaluated the association between…
Rank50.0
Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population.
Journal of medical economics · 2026 · PMID 41705966
AIM: Conventional therapies in Japan for relapsed or refractory large B-cell lymphoma (r/r LBCL) require intravenous infusion (IV), while epcoritamab is administered subcutaneously. Despite the expected quality of life (QOL) improvement from reduced drug administration burden, limited data exists on QOL for common r/r LBCL treatment modalities. This study aimed to estimate the impact of drug administration on QOL (i.e. process utility) across treatments for r/r LBCL using responses from the Japanese general populat…
Rank49.8
Optimized PET/CT response assessment for prognostic stratification compared with Lugano criteria in extranodal NK/T-Cell lymphoma.
European journal of nuclear medicine and molecular imaging · 2026 · PMID 42191947
PURPOSE: Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive malignancy and usually involves the nasal cavity. Although the Lugano criteria is widely used for lymphoma response assessment, its applicability in ENKTL is limited by reliance on a single pre-treatment reference and a positive reference threshold with high false-positive rate. This study proposed and evaluated the ability of a novel evaluation system derived from the Lugano criteria to predict ENKTL treatment response. METHODS: A total of…
Rank49.1
Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies.
International journal of laboratory hematology · 2026 · PMID 41821147
INTRODUCTION: Neutrophil-extracellular traps are net-like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil-specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation of extracellular matrix and has proinflammatory functions. METHODS: Plasma was obtained from 111 patients with various hematological malignancies and 42 healthy donors, and p…
Rank49.1
Long-term outcomes in juvenile-onset mycosis fungoides.
Journal of the American Academy of Dermatology · 2026 · PMID 41780598
BACKGROUND: Mycosis fungoides is the most common cutaneous T-cell lymphoma in the pediatric population. OBJECTIVE: We aimed to characterize the long-term outcomes associated with juvenile-onset mycosis fungoides (jMF). METHODS: Patients were identified from a retrospective database. Clinical and histopathologic data were obtained from medical records, and survival was assessed through contact by telemedicine. Stage progression was defined as progression to a more advanced tumor, node, metastasis, and blood stage or…
Rank49.0
Risk Stratification in Pediatric Non-Hodgkin Lymphoma Using Maximum Tumor Dissemination and Metabolic Tumor Burden on Baseline 18 F-FDG PET/CT.
Clinical nuclear medicine · 2026 · PMID 42302721
BACKGROUND: Pediatric non-Hodgkin lymphoma (NHL) is the third most common childhood malignancy, but reliable prognostication remains challenging. This study aimed to evaluate the prognostic value of baseline 18 F-FDG PET/CT parameters reflecting disease spread, the largest interlesion distance (Dmax), and total metabolic tumor volume (TMTV), in pediatric patients with NHL. PATIENTS AND METHODS: We retrospectively enrolled 98 pediatric patients with NHL (74 males, 24 females; median age, 10.4 y; range, 0.3-17.9 y) w…
Rank49.0
Cancer treatment-related cardiovascular toxicity according to the ESC definition in patients receiving CAR T-cell therapy.
Cardio-oncology (London, England) · 2026 · PMID 42538564
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has substantially improved outcomes in refractory hematologic malignancies but may cause cardiovascular complications, particularly in the context of cytokine release syndrome (CRS). Real-world data on incidence, severity, and prognostic relevance of cancer therapy-related cardiovascular toxicity (CTR-CVT) defined by the 2022 ESC cardio-oncology guidelines remain in the context of CAR-T cell therapy limited. METHODS: This retrospective single-center study i…
Rank48.9
Risk Factors of Disseminated Tumor Cells in the Bone Marrow of Patients With Angioimmunoblastic T-Cell Lymphoma and Their Impact on Prognosis.
International journal of laboratory hematology · 2026 · PMID 41957877
INTRODUCTION: Angioimmunoblastic T-cell lymphoma (AITL) is a mature T-cell proliferative tumor characterized by an aggressive clinical course and low incidence. The risk factors for the presence of disseminated tumor cells (DTCs) in the bone marrow (BM) of patients and their impact on prognosis remain incompletely understood. In this study, we used multiparametric flow cytometry (MFC) to detect DTCs in the BM of AITL patients. We aimed to assess risk factors for the presence of DTCs, investigate correlations betwee…
Rank48.7
Primary bone lymphoma: a radiologic-pathologic series of 72 cases uncovering the diagnostic complexity of a rare and heterogeneous entity.
Skeletal radiology · 2026 · PMID 42542494
INTRODUCTION: Primary bone lymphoma (PBL) is a rare extranodal lymphoma accounting for approximately 7% of malignant primary bone tumors. It typically presents with nonspecific features, frequently resulting in diagnostic delay and inappropriate initial management. MATERIAL AND METHODS: We retrospectively analyzed the characteristics of 72 patients diagnosed with PBL between 1966 and 2025 at a tertiary referral center in Spain. RESULTS: Diffuse large B-cell lymphoma (DLBCL) was the predominant histological subtype.…
Evidence Syntheses62 records
Rank112.0
[China lymphoma diagnosis and treatment guideline (2026 edition)].
Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 41876194
Lymphoma is one of the most common malignancies in China. Lymphoma exhibited complex pathological subtypes with significant heterogeneity, the treatment strategies varied. In recent years, with a deeper understanding of the mechanisms of oncogenesis and disease progression of lymphoma, significant development has been made in diagnosis and treatment, leading to the improvement of patients' clinical outcomes. In order to update the progress in the diagnosis and treatment of lymphoma. The Medical Oncology Branch of C…
Rank109.5
Association between interleukin-10 (IL-10) genetic polymorphisms and non-hodgkin lymphoma: a systematic review and meta-analysis.
Leukemia & lymphoma · 2026 · PMID 42335190
Non-Hodgkin lymphoma (NHL) has been associated with IL-10 single-nucleotide polymorphisms (SNPs), although findings remain inconsistent. This meta-analysis aims to investigate the association between key IL-10 SNPs (rs1800871, rs1800872, rs1800890, and rs1800896) with NHL. A systematic search of multiple databases was conducted to get relevant articles. The study included 53,864 cases and 60,448 controls from 41 studies. Pooled ORs with 95% CIs were calculated for each SNP, along with a heterogeneity test and publi…
Rank108.2
Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.
Transplantation and cellular therapy · 2026 · PMID 41525947
In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…
Rank107.8
Understanding the factors influencing quality of life among survivors of Non-Hodgkin lymphoma after completing primary treatment: a systematic review.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 41774244
PURPOSE: To evaluate and synthesize the existing evidence on factors influencing the quality of life (QoL) of non-Hodgkin lymphoma (NHL) survivors and the impact of these factors on their QoL. METHODS: A systematic review was conducted following PRISMA guidelines, with searches in CINAHL, MEDLINE, PubMed, ScienceDirect, Scopus, and Web of Science. Studies published between 2014 and 2025 were included if they were original English-language research involving adult (age ≥ 18 years) NHL survivors and focused on factor…
Rank107.8
Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.
The Lancet. Haematology · 2026 · PMID 42069410
BACKGROUND: The treatment landscape for relapsed or refractory diffuse large B-cell lymphoma has changed profoundly with the introduction of novel drug classes, some approved solely on the basis of single-arm early-phase trials. We aimed to evaluate antitumour activity and safety outcomes across drug classes in early-phase trials in relapsed or refractory diffuse large B-cell lymphoma since 2000. METHODS: We did a systematic review and meta-analysis of phase 1-2 trials. We searched PubMed, Embase.com, Web of Scienc…
Rank107.6
Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42177127
INTRODUCTION: Survival outcomes of patients with mantle cell lymphoma (MCL) have substantially improved. In the setting of extended overall survival (OS), progression-free survival (PFS) is typically used as a primary endpoint in MCL clinical trials rather than OS to limit trial duration and cost. However, no prior analysis has assessed whether PFS can reliably predict OS. The aim of this study is to perform a systematic evaluation of PFS as a surrogate endpoint for OS in phase III MCL clinical trials. MATERIALS AN…
Rank106.9
Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.
Frontiers in immunology · 2026 · PMID 42495620
This meta-analysis compared chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), focusing on efficacy and safety. We analyzed 59 phase I/II trials involving 2,914 patients. CAR-T achieved higher ORR (72% [95% CI 67-77%] vs. 50% [38-62%]) and CR (54% [49-59%] vs. 33% [23-46%]) than BsAbs. However, it was associated with higher rates of grade ≥3 CRS (8% [6-11%] vs. 4% [3-7%]), ICANS (12% [9-16%] vs. 6% [2-18%]), and neuroto…
Rank106.7
Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.
Acta neurologica Belgica · 2026 · PMID 41212511
BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma, most often a diffuse large B-cell lymphoma. Rituximab, an anti-CD20 monoclonal antibody is widely used in PCNSL treatment but its efficacy remains uncertain. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy of rituximab in newly diagnosed adult PCNSL patients. METHODS: Medline/PubMed and Scopus were searched for studies comparing rituximab/rituximab-contai…
Rank106.7
Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis.
PeerJ · 2026 · PMID 42428526
BACKGROUND AND OBJECTIVES: Large B-cell lymphoma (LBCL) is a common and aggressive non-Hodgkin lymphoma (NHL) characterized by abnormal proliferation of mature B lymphocytes, with a 10-year prevalence of up to 45 cases per 100,000 individuals in European populations and a continuing upward trend. Axicabtagene ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) are the two most established chimeric antigen receptor T-cell (CAR-T) therapy products for LBCL, yet a systematic comparison of their efficacy and safety in…
Rank106.7
CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.
La Clinica terapeutica · 2026 · PMID 42340791
BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a major therapeutic challenge, particularly among patients with high-risk molecular features or primary refractory disease. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment strategy; however, its comparative effectiveness versus salvage chemotherapy requires comprehensive evaluation. METHODS: This systematic review and meta-analysis were conducted in accordance with PRISMA 2020 and MOOSE guideli…
Rank106.4
Progression-free survival is strongly associated with overall survival in relapsed/refractory diffuse large B-cell lymphoma in the CAR T-cell era.
Journal of cancer policy · 2026 · PMID 41429401
INTRODUCTION: In clinical trials for diffuse large B-cell lymphoma (DLBCL), progression-free survival (PFS) has been used as a validated surrogate endpoint to help expedite drug development and regulatory approval. The advent of chimeric antigen receptor (CAR) T-cell therapies has radically changed the treatment landscape, potentially prolonging post-progression survival and weakening the correlation between PFS and overall survival (OS). This study evaluates the utility of PFS as a surrogate endpoint for OS in rel…
Rank106.3
Efficacy of zanubrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 41786108
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma, and previous studies have indicated the potential of zanubrutinib in the treatment of DLBCL. This meta-analysis aims to evaluate the efficacy of zanubrutinib in DLBCL patients and further explore potential differences in treatment effects across diverse patient subgroups. METHODS: A systematic literature search was conducted using two major databases (PubMed and Embase) and four key conference websites to e…
Rank106.2
Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.
Blood advances · 2026 · PMID 41587420
Follicular lymphoma with progression of disease within 24 months (POD24) is associated with poor prognosis and represents clinical challenges. Therefore, we performed a systematic review and pooled analysis of patients with POD24. Twenty-one trials involving 1242 participants were included, assessing the overall response rate (ORR), complete response (CR), duration of response, and progression-free survival. In some trials, we compared pooled response rates between POD24 and non-POD24 populations with the same trea…
Rank106.1
Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.
Annals of hematology · 2026 · PMID 42118323
Patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who experience disease progression following anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy face poor prognoses and limited therapeutic options. Bispecific antibodies (BsAbs) have emerged as a promising salvage strategy. This meta-analysis was conducted to evaluate the efficacy and safety of CD3×CD20 BsAbs in R/R LBCL patients after CAR-T failure. Clinical studies published between 2021 and 2025 were systematically reviewed, and a r…
Rank106.1
Systematic review and meta-analysis of PET-based prognostic metrics in CAR-T treatment of DLBCL.
Frontiers in immunology · 2026 · PMID 41816336
OBJECTIVES: This study aims to conduct a systematic review and meta-analysis to investigate how imaging parameters derived from 18F-FDG positron emission tomography/computed tomography (PET/CT) predict treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) receiving chimeric antigen receptor T-cell (CAR-T) therapy. METHODS: A comprehensive search was conducted in PubMed, Embase, Cochrane Library, and Web of Science databases to retrieve relevant literature from their inception to December 24, 202…
Rank105.6
Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.
Cancer · 2026 · PMID 42487493
BACKGROUND: Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, is a therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after chimeric antigen receptor T-cell therapy. This study summarized efficacy and safety across published cohorts. METHODS: The authors did a systematic review and meta-analysis of loncastuximab tesirine monotherapy in adults with relapsed or refractory DLBCL. They searched PubMed, Embase, and the Cochrane Library from inception to October 25, 2025, plus…
Rank105.5
Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352
INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …
Rank105.1
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
Journal of medical economics · 2026 · PMID 42452801
OBJECTIVE: No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL). METHODS: Following a systematic literature review, individual patient data from trials of zanubrutinib (n = 118) and aggregate data from a pooled analysis of ibrutinib trials (n = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC). RESULTS: After matching selected covariates, statistically significant differences were observed with zanu…
Rank105.1
The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42409674
The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the …
Rank103.2
Systemic Glucocorticoid Use and Risk of Site-Specific Cancers: A Methodologic Systematic Review of Observational Studies.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · PMID 41931525
Systemic glucocorticoids, widely prescribed for inflammatory and autoimmune diseases, have long been suspected of increasing cancer risk through immunosuppressive and metabolic effects. Randomized trials are often unethical and difficult to conduct, leaving observational studies the best option to determine whether the use of systemic glucocorticoids affects cancer development. However, these studies face significant methodologic issues that may compromise the validity of their findings. We systematically reviewed …
Rank103.1
Breast implant-associated B-cell lymphomas: First systematic review of the literature.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2026 · PMID 41932273
INTRODUCTION: Although breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a T-cell lymphoma, is well characterized, recent reports have highlighted B-cell lymphomas associated with breast implants, a less understood and distinct entity. OBJECTIVE: This systematic review aimed to investigate breast implant-associated B-cell lymphomas (BIA-BCL) by analyzing their clinical presentation, diagnostic workup, histopathology, management, and prognosis. METHODS: A comprehensive literature search was perfor…
Rank103.0
[Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026 · PMID 42409743
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive type of intestinal T-cell lymphoma. With the application of high-throughput sequencing technologies in recent years, the understanding of this entity has become increasingly comprehensive. The World Health Organization classification of lymphoma now recognizes MEITL as a distinct disease entity. However, the extreme rarity of MEITL poses substantial challenges for clinical diagnosis and management, and patient outcomes re…
Rank103.0
Single-cell RNA sequencing unveils CD8+ T cell heterogeneity in the diffuse large B-cell lymphoma microenvironment: A systematic review.
Critical reviews in oncology/hematology · 2026 · PMID 42144172
BACKGROUND: The heterogeneous response to immunotherapy in diffuse large B-cell lymphoma (DLBCL) is largely attributable to the diverse functional states of CD8⁺ T cells within the tumor microenvironment. Although single-cell RNA sequencing (scRNA-seq) has revolutionized cellular resolution, a systematic synthesis of this evidence to map CD8⁺ T cell heterogeneity and its clinical implications in DLBCL is currently lacking. METHODS: Following the PRISMA guidelines and a PROSPERO-registered protocol (CRD420261282336)…
Rank102.9
Prognostic Value of Interim [18F]FDG PET in Large B-Cell Lymphoma: A Systematic Review and Meta-analysis with a Particular Focus on Interim Deauville Score 5 Disease.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · PMID 41545069
Our rationale was to investigate the potential of interim [18F]FDG PET (iPET) in predicting large B-cell lymphoma (LBCL) patients' outcomes, including the end-of-treatment response, progression-free survival (PFS), and overall survival (OS). Methods: A systematic search was conducted on the 3 main medical literature databases until January 8, 2025. Published original articles that evaluated iPET for prognosticating LBCL patients and provided crude data for meta-analytic calculations were considered eligible. The hi…
Rank102.0
T-cell receptor beta constant 1 flow cytometry for diagnosing clonality in mature T-cell neoplasms: a systematic review and meta-analysis of diagnostic accuracy.
Clinical chemistry and laboratory medicine · 2026 · PMID 41712312
INTRODUCTION: Accurate assessment of T-cell clonality is key for diagnosing mature T-cell neoplasms. TRBC1-based flow cytometry provides a rapid, robust, and cost-efficient approach. This systematic review and meta-analysis assessed the diagnostic accuracy of TRBC1 flow cytometry (TRBC1-FC) for detecting T-cell clonality in mature T-cell neoplasms. CONTENT: We systematically searched Scopus, PubMed (MEDLINE), and Google Scholar for articles on TRBC1-FC diagnostic accuracy published up to July 1, 2025. Pooled sensit…
Landmark Evidence35 records
Rank108.2
Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.
Transplantation and cellular therapy · 2026 · PMID 41525947
In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…
Rank108.0
Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.
Transplantation and cellular therapy · 2024 · PMID 38972511
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL), accounting for nearly one-third of all NHL. The therapeutic landscape for patients with FL has significantly expanded over the past decade, but the disease continues to be considered incurable. Hematopoietic cell transplantation (HCT) is potentially curative in some cases. Recently, the emergence of chimeric antigen receptor T-cell therapy (CAR-T) for patients with relapsed/refractory (R/R) FL has yielded impressive response rat…
Rank107.0
Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.
Blood advances · 2025 · PMID 40590871
CD3xCD20 bispecific antibody (BsAb) therapy and CD19-directed chimeric antigen receptor T-cell therapy (CAR T) are novel immunotherapies that have shown impressive efficacy in B-cell lymphomas, but also come with significant morbidity and mortality, including infections. This meta-analysis compares rates of infections between commercially approved CAR T and BsAb therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL). We conducted a systematic review for prospective trials assessing commercially approved CAR T…
Rank106.9
Genetic susceptibility of diffuse large B-cell lymphoma: a meta genome-wide association study in Asian population.
Leukemia · 2025 · PMID 39707004
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and the most common form of non-Hodgkin lymphoma (NHL) that occurs worldwide. To discover risk factors and pathogenesis of DLBCL, we performed the largest GWAS of DLBCL to date in samples of East Asian ancestry, consisting of 2,888 patients with DLBCL and 12,458 controls. The meta-analysis identified three novel loci, rs2233434 on 6p21.1 (OR = 1.26, P = 1.17 × 10-8), rs11066015 on 12q24.12 (OR = 1.24, P = 6.57 × 10-9) and rs6032662 on 20q13.12 (OR = …
Rank105.5
Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352
INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …
Rank105.1
The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42409674
The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the …
Rank105.0
Benzene exposure and non-Hodgkin lymphoma: a systematic review and meta-analysis of human studies.
The Lancet. Planetary health · 2021 · PMID 34450064
BACKGROUND: Non-Hodgkin lymphoma comprises a heterogeneous group of cancers with unresolved aetiology, although risk factors include environmental exposures to toxic chemicals. Although the ubiquitous pollutant benzene is an established leukemogen, its potential to cause non-Hodgkin lymphoma has been widely debated. We aimed to examine the potential link between benzene exposure and risk of non-Hodgkin lymphoma in humans by evaluating a wide array of cohort and case-control studies using electronic systematic revie…
Rank104.9
Diabetes and the Prognosis in Patients With Non-Hodgkin Lymphoma: A Meta-analysis of Cohort Studies.
Clinical lymphoma, myeloma & leukemia · 2022 · PMID 34593361
BACKGROUND: Consensus lacks regarding the association between diabetes mellitus (DM) and the prognosis of patients with non-Hodgkin lymphoma (NHL). We aimed to systematically evaluate the above association, as well as the potential influence of metformin use in a meta-analysis of cohort studies. MATERIALS AND METHODS: Cohort studies investigating the association between DM and survival outcomes of patients with NHL were included by search of electronic databases that included PubMed, Embase, and Web of Science. A r…
Rank104.1
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
Cancer research and treatment · 2023 · PMID 36915243
PURPOSE: We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis. MATERIALS AND METHODS: R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and chimeric antigen receptor (CAR) T-cell therapy was used as reference treatment.…
Rank103.9
Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry.
Blood reviews · 2021 · PMID 33187810
The clinical relevance of flow cytometry (FC)-based bone marrow involvement (BMI) in B cell non-Hodgkin lymphoma (B-NHL) is not well established. We conducted a systematic review of MEDLINE regarding the use of FC to establish BMI in B-NHL to determine the prevalence of BMI by FC, to understand the interrelation between FC and bone marrow biopsy (BMB), and to explore the prognostic impact of BMI by FC. Relevant exclusion criteria included publication before 2010. Eleven publications (of 18 screened) were included, …
Rank103.0
[Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026 · PMID 42409743
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive type of intestinal T-cell lymphoma. With the application of high-throughput sequencing technologies in recent years, the understanding of this entity has become increasingly comprehensive. The World Health Organization classification of lymphoma now recognizes MEITL as a distinct disease entity. However, the extreme rarity of MEITL poses substantial challenges for clinical diagnosis and management, and patient outcomes re…
Rank102.6
A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
Frontiers in immunology · 2023 · PMID 37180149
UNLABELLED: Chimeric antigen receptor (CAR) T-cells are an emerging therapy for the treatment of relapsed/refractory B-cell malignancies. While CD19 CAR-T cells have been FDA-approved, CAR T-cells targeting CD22, as well as dual-targeting CD19/CD22 CAR T-cells, are currently being evaluated in clinical trials. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of CD22-targeting CAR T-cell therapies. We searched MEDLINE, EMBASE, Web of Science, and the Cochrane Central Register of Con…
Rank102.0
Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.
International journal of radiation oncology, biology, physics · 2014 · PMID 24725689
Radiation therapy (RT) is the most effective single modality for local control of non-Hodgkin lymphoma (NHL) and is an important component of therapy for many patients. Many of the historic concepts of dose and volume have recently been challenged by the advent of modern imaging and RT planning tools. The International Lymphoma Radiation Oncology Group (ILROG) has developed these guidelines after multinational meetings and analysis of available evidence. The guidelines represent an agreed consensus view of the ILRO…
Rank101.1
Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients.
Medicine · 2017 · PMID 28858138
BACKGROUND: Non-Hodgkin lymphoma (NHL) is a group of lymphoproliferative malignancies with varying treatment responses and progression-free survival (PFS) times. The objective of this study was to quantify the effect of treatment and patient-population characteristics on PFS in patients with NHL. METHODS: A database was developed from 513 NHL clinical trials reported from 1993 to 2015. Summary-level PFS was obtained from 112 of these trials, which included 155 cohorts and 11,824 patients. Characteristics evaluated …
Rank100.0
Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.
Cancer · 2024 · PMID 38041532
BACKGROUND: The emergence of novel and efficient antibody maintenance approaches has provided more options for post-induction treatment of advanced follicular lymphoma (FL), and further comparisons are required to determine the most clinically beneficial regimen. The authors conducted a systematic review and meta-analysis to evaluate the maintenance or consolidation strategy. METHODS: The authors performed two independent searches in PubMed, Web of Science, the Cochrane library databases, Scopus, and Embase for ran…
Rank100.0
A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
The oncologist · 2024 · PMID 38207010
PURPOSE: The clinical efficacy of anti-CD20 radioimmunotherapy (RIT) is due to a combination of extracellular mechanisms involving immune-mediated cytotoxicity, and intracellular mechanisms related to inhibition of CD20 signaling and DNA damage from ionizing radiation. In 2002, the first RIT was approved by the U.S. Food and Drug Administration for the treatment of patients with indolent B-cell follicular non-Hodgkin lymphoma (NHL). The 2 approved agents, 90 Y-ibritumomab tiuxetan (90Y-IT, Zevalin, Acrotech Biophar…
Rank100.0
Non-Hodgkin's lymphomas, version 2.2014.
Journal of the National Comprehensive Cancer Network : JNCCN · 2014 · PMID 24925202
Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherap…
Rank98.3
Non-Hodgkin's lymphomas (NHL).
Acta oncologica (Stockholm, Sweden) · 1996 · PMID 9154102
This synthesis of the literature on radiotherapy for non-Hodgkin's lymphomas is based on 158 scientific articles, including 16 randomized studies, 18 prospective studies, and 90 retrospective studies. These studies involve 14,137 patients. Non-Hodgkin's lymphomas are highly radiosensitive, and local recurrence following radiotherapy is unusual. Radiotherapy probably cures approximately 50% of both low-grade and high-grade malignant NHL at stage I. Involved field is apparently sufficient, however, higher doses are r…
Rank98.0
Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis.
Scientific reports · 2025 · PMID 40456850
Confirming the patient benefit of progression-free survival (PFS) in B-cell non-Hodgkin lymphoma (B-NHL) and multiple myeloma (MM) has become increasingly challenging due to the improved outcomes brought by novel therapies. In parallel, the U.S. Food and Drug Administration recommends conducting randomized trials, focusing on evaluating early endpoints to compare study and control arms for accelerated approval (AA). From both the clinical and regulatory perspectives, identifying early surrogate endpoints for PFS is…
Rank97.1
Treatment of Parotid Non-Hodgkin Lymphoma: A Meta-Analysis.
Journal of global oncology · 2018 · PMID 30241143
PURPOSE: This meta-analysis aimed to review the published outcomes of parotid non-Hodgkin lymphoma (NHL) pertaining to different treatment modalities. MATERIALS AND METHODS: A total of 48 journal articles published between 1993 and 2015, comprising 742 cases of parotid NHL, were initially evaluated. In total, 108 patients from 12 studies who had sufficient data for analysis, including age, tumor histopathology, treatment modality, and outcome at final follow-up, were included. Patients were randomly assigned to dif…
Rank97.0
Prognostic Value of Microvessel Density in Non-Hodgkin Lymphoma: A Meta-Analysis.
Acta haematologica · 2021 · PMID 34044389
BACKGROUND: Angiogenesis in non-Hodgkin lymphoma (NHL) has been investigated by a variety of studies. However, the correlation between angiogenesis and the occurrence or prognosis of NHL patients remains controversial. METHODS: We performed a systematic and comprehensive retrieval of relevant literatures from PubMed, EMBASE, and Web of Science databases. The quality of the eligible studies was assessed using the Newcastle-Ottawa Scale (NOS). RESULTS: Fifteen eligible studies containing a total of 1373 NHL patients …
Rank97.0
Systematic review of the potential of MicroRNAs in the management of patients with follicular lymphoma.
Critical reviews in oncology/hematology · 2021 · PMID 33515703
Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma and usually presents as an indolent disease. However, some patients present poor outcomes, and FL can transform into more aggressive lymphomas, such as Diffuse Large B cell lymphoma (DLBCL). MicroRNAs (miRNA) are small RNA molecules that participate in posttranscriptional regulation of gene expression, that are emerging biomarkers in cancer. In this systematic review, we included studies evaluating miRNA expression in tumor tissue as diagnosis,…
Rank97.0
Diesel exhaust exposure and risk of non-Hodgkin lymphoma: a meta-analysis.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2022 · PMID 34750336
OBJECTIVE: We aimed at carrying out a systematic review and meta-analysis of epidemiological studies on the association between occupational and non-occupational exposures to diesel exhaust and risk of non-Hodgkin lymphoma. METHODS: We conducted a systematic search of the literature and identified 16 cohort studies and 7 case-control studies that analyzed non-Hodgkin lymphoma alone or combined with Hodgkin lymphoma or multiple myeloma, from which we extracted 29 independent risk estimates. We performed random-effec…
Rank97.0
Exposure to glyphosate and risk of non-Hodgkin lymphoma: an updated meta-analysis.
La Medicina del lavoro · 2021 · PMID 34142676
OBJECTIVE: We updated a recent systematic review and meta-analysis of epidemiologic studies to help clarifying the association between exposure to glyphosate and risk of non-Hodgkin lymphoma (NHL). METHODS: We conducted an updated search of the literature, and identified a total of 15 relevant publications, from which we extracted results from six non-overlapping studies. We performed random-effects meta-analyses for ever-exposure to glyphosate, dose-response, and risk of specific NHL subtypes Results: The meta-RR …
Rank97.0
Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.
Cancer science · 2021 · PMID 33938097
Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose adjustments to avoid overdose and toxicities. Conversely, some drugs are removed by HD and may expose the patient to undertreatment, therefore the timing of drug administration in relation to HD sessions must be carefully planned. Also, the metabolites of some drugs show …
Most Effective Evidence Supported Treatments65 records
Rank108.2
Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.
Transplantation and cellular therapy · 2026 · PMID 41525947
In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…
Rank107.8
Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.
The Lancet. Haematology · 2026 · PMID 42069410
BACKGROUND: The treatment landscape for relapsed or refractory diffuse large B-cell lymphoma has changed profoundly with the introduction of novel drug classes, some approved solely on the basis of single-arm early-phase trials. We aimed to evaluate antitumour activity and safety outcomes across drug classes in early-phase trials in relapsed or refractory diffuse large B-cell lymphoma since 2000. METHODS: We did a systematic review and meta-analysis of phase 1-2 trials. We searched PubMed, Embase.com, Web of Scienc…
Rank107.6
Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42177127
INTRODUCTION: Survival outcomes of patients with mantle cell lymphoma (MCL) have substantially improved. In the setting of extended overall survival (OS), progression-free survival (PFS) is typically used as a primary endpoint in MCL clinical trials rather than OS to limit trial duration and cost. However, no prior analysis has assessed whether PFS can reliably predict OS. The aim of this study is to perform a systematic evaluation of PFS as a surrogate endpoint for OS in phase III MCL clinical trials. MATERIALS AN…
Rank106.9
Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.
Frontiers in immunology · 2026 · PMID 42495620
This meta-analysis compared chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), focusing on efficacy and safety. We analyzed 59 phase I/II trials involving 2,914 patients. CAR-T achieved higher ORR (72% [95% CI 67-77%] vs. 50% [38-62%]) and CR (54% [49-59%] vs. 33% [23-46%]) than BsAbs. However, it was associated with higher rates of grade ≥3 CRS (8% [6-11%] vs. 4% [3-7%]), ICANS (12% [9-16%] vs. 6% [2-18%]), and neuroto…
Rank106.7
Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis.
PeerJ · 2026 · PMID 42428526
BACKGROUND AND OBJECTIVES: Large B-cell lymphoma (LBCL) is a common and aggressive non-Hodgkin lymphoma (NHL) characterized by abnormal proliferation of mature B lymphocytes, with a 10-year prevalence of up to 45 cases per 100,000 individuals in European populations and a continuing upward trend. Axicabtagene ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) are the two most established chimeric antigen receptor T-cell (CAR-T) therapy products for LBCL, yet a systematic comparison of their efficacy and safety in…
Rank106.7
CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.
La Clinica terapeutica · 2026 · PMID 42340791
BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a major therapeutic challenge, particularly among patients with high-risk molecular features or primary refractory disease. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment strategy; however, its comparative effectiveness versus salvage chemotherapy requires comprehensive evaluation. METHODS: This systematic review and meta-analysis were conducted in accordance with PRISMA 2020 and MOOSE guideli…
Rank106.7
Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.
Acta neurologica Belgica · 2026 · PMID 41212511
BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma, most often a diffuse large B-cell lymphoma. Rituximab, an anti-CD20 monoclonal antibody is widely used in PCNSL treatment but its efficacy remains uncertain. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy of rituximab in newly diagnosed adult PCNSL patients. METHODS: Medline/PubMed and Scopus were searched for studies comparing rituximab/rituximab-contai…
Rank106.3
Efficacy of zanubrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 41786108
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma, and previous studies have indicated the potential of zanubrutinib in the treatment of DLBCL. This meta-analysis aims to evaluate the efficacy of zanubrutinib in DLBCL patients and further explore potential differences in treatment effects across diverse patient subgroups. METHODS: A systematic literature search was conducted using two major databases (PubMed and Embase) and four key conference websites to e…
Rank106.1
Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.
Annals of hematology · 2026 · PMID 42118323
Patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who experience disease progression following anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy face poor prognoses and limited therapeutic options. Bispecific antibodies (BsAbs) have emerged as a promising salvage strategy. This meta-analysis was conducted to evaluate the efficacy and safety of CD3×CD20 BsAbs in R/R LBCL patients after CAR-T failure. Clinical studies published between 2021 and 2025 were systematically reviewed, and a r…
Rank105.6
Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.
Cancer · 2026 · PMID 42487493
BACKGROUND: Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, is a therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after chimeric antigen receptor T-cell therapy. This study summarized efficacy and safety across published cohorts. METHODS: The authors did a systematic review and meta-analysis of loncastuximab tesirine monotherapy in adults with relapsed or refractory DLBCL. They searched PubMed, Embase, and the Cochrane Library from inception to October 25, 2025, plus…
Rank105.5
Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352
INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …
Rank105.1
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
Journal of medical economics · 2026 · PMID 42452801
OBJECTIVE: No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL). METHODS: Following a systematic literature review, individual patient data from trials of zanubrutinib (n = 118) and aggregate data from a pooled analysis of ibrutinib trials (n = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC). RESULTS: After matching selected covariates, statistically significant differences were observed with zanu…
Rank105.1
The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42409674
The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the …
Rank103.1
Breast implant-associated B-cell lymphomas: First systematic review of the literature.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2026 · PMID 41932273
INTRODUCTION: Although breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a T-cell lymphoma, is well characterized, recent reports have highlighted B-cell lymphomas associated with breast implants, a less understood and distinct entity. OBJECTIVE: This systematic review aimed to investigate breast implant-associated B-cell lymphomas (BIA-BCL) by analyzing their clinical presentation, diagnostic workup, histopathology, management, and prognosis. METHODS: A comprehensive literature search was perfor…
Rank103.0
Single-cell RNA sequencing unveils CD8+ T cell heterogeneity in the diffuse large B-cell lymphoma microenvironment: A systematic review.
Critical reviews in oncology/hematology · 2026 · PMID 42144172
BACKGROUND: The heterogeneous response to immunotherapy in diffuse large B-cell lymphoma (DLBCL) is largely attributable to the diverse functional states of CD8⁺ T cells within the tumor microenvironment. Although single-cell RNA sequencing (scRNA-seq) has revolutionized cellular resolution, a systematic synthesis of this evidence to map CD8⁺ T cell heterogeneity and its clinical implications in DLBCL is currently lacking. METHODS: Following the PRISMA guidelines and a PROSPERO-registered protocol (CRD420261282336)…
Rank103.0
[Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026 · PMID 42409743
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive type of intestinal T-cell lymphoma. With the application of high-throughput sequencing technologies in recent years, the understanding of this entity has become increasingly comprehensive. The World Health Organization classification of lymphoma now recognizes MEITL as a distinct disease entity. However, the extreme rarity of MEITL poses substantial challenges for clinical diagnosis and management, and patient outcomes re…
Rank101.0
The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.
Hematological oncology · 2026 · PMID 42062177
The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B-cell lymphoma (DLBCL). Treatment consisted of six cycles of R-CHOP + 2xR or DA-EPOCH-R + 2xR. Patients with intermediate or high-risk CNS International Prognostic Index (CNS-IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m2 i.v. (arm A) or 6 doses of MTX 12 mg i.t. (arm B). P…
Rank100.2
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
Lancet (London, England) · 2026 · PMID 42217458
BACKGROUND: Approximately 40% of patients with high-risk diffuse large B-cell lymphoma (DLBCL) are not cured with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone). We aimed to investigate the addition of tafasitamab (an Fc-enhanced anti-CD19 monoclonal antibody) and lenalidomide to R-CHOP (tafa-len-R-CHOP) in patients with high-risk aggressive B-cell lymphomas. METHODS: frontMIND is a phase 3, randomised, double-blind, placebo-controlled study conducted at 29…
Rank100.0
The pharmacokinetics and its covariates of rituximab in different clinical populations: a systematic review and narrative synthesis.
European journal of clinical pharmacology · 2026 · PMID 42426484
INTRODUCTION: The regimen of rituximab we not determined based on evidence from pharmacokinetics. However, rituximab exhibited significant pharmacokinetic variability among different clinical populations, which might be a key factor influencing individual exposure and response to this monoclonal antibody. This systematic review aimed to analyze the traditional and population pharmacokinetics of rituximab and to investigate covariates influencing its pharmacokinetics. METHODS: A systematic search was conducted in th…
Rank100.0
Rescue Protocols for Canine Non-Indolent B Cell Lymphoma: A Systematic Review.
Veterinary and comparative oncology · 2026 · PMID 41656180
Canine lymphoma is a heterogenous group of diseases. The most common subtype is diffuse large B cell lymphoma (DLBCL), though definitive diagnosis beyond non-indolent = multicentric B cell lymphoma is not often achieved in clinical practice as it requires histopathology. Most dogs respond well to standard-of-care multiagent chemotherapy (CHOP) but relapse and eventual CHOP-resistance is likely. Less commonly there is a lack of complete response to initial CHOP treatment. CHOP-resistant cases are treated with rescue…
Rank100.0
Rare colorectal manifestations of pediatric gastrointestinal lymphoma: a systematic review of clinical spectrum and surgical implications.
Pediatric surgery international · 2026 · PMID 42437396
PURPOSE: Pediatric colorectal malignancies are rare, with lymphomas- predominantly non- Hodgkin's lymphoma (NHL) representing the most common type, accounting to 0.5-2% of large bowel malignancies. Colorectal NHL can be primary or secondary. This study analyzes the rare manifestations of pediatric colorectal lymphoma and examines their diagnostic challenges and surgical implications. METHOD: A Pubmed search was done with search words "lymphoma of colon pediatric" with filter of last 5 years on 12 Feb 2026. The sear…
Rank100.0
Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis.
Annals of hematology · 2026 · PMID 42053782
Both anti-CD19 chimeric antigen receptor (CAR)-T cell therapy and CD20xCD3 bispecific antibodies (BsAbs) are recommended as preferred regimens of third-line and subsequent treatment for follicular lymphoma (FL). We aimed to compare the efficacy and safety of CAR-T and BsAbs in third- or later-line treatments for relapsed or refractory (R/R) FL. We reviewed trials from PubMed, Embase and Cochrane Library databases up to January 31, 2025. Primary endpoint was overall response rate (ORR). Secondary endpoints included …
Rank100.0
Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review.
Leukemia & lymphoma · 2026 · PMID 41866227
T-cell-directed immunotherapies, including chimeric antigen receptor T-cell therapy (CAR-T) and bispecific antibodies (BsAbs), have revolutionized the management of B-cell lymphomas, yet options after treatment failure remain limited. We reviewed four patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) after BsAb or CAR-T exposure, and performed a systematic literature review. Three patients had large B-cell lymphoma, one had follicular lymphoma. Two achieved durable remission, whe…
Rank100.0
Lymphoma Related to the Ventricular System: A Rare Case Report and Systematic Review of Intraventricular Lymphomas.
Medical sciences (Basel, Switzerland) · 2026 · PMID 42201003
Background: Intraventricular central nervous system (CNS) lymphoma is an atypical presentation of extranodal lymphoma, whether primary or secondary. The most commonly diagnosed subtype of lymphoma is diffuse large B-cell lymphoma (DLBCL). There is a documented relation of HIV, EBV and KSHV infections with lymphomagenesis. AIDS-related lymphomas (ARLs) are described as a defining illness of the acquired immunodeficiency syndrome (AIDS). This study presents a novel case and systematic review of clinical, radiographic…
Rank100.0
Efficacy and Safety of Mogamulizumab for Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42236443
Cutaneous T-cell lymphomas (CTCL) are heterogeneous skin malignancies. Mycosis fungoides (MF), followed by Sézary syndrome (SS), are the most prevalent. Mogamulizumab demonstrated a superior overall response rate (ORR) compared to vorinostat in the MAVORIC phase III trial, leading to regulatory approval for relapsed/refractory MF/SS; real-world efficacy remains poorly characterized. No systematic review has integrated the trial evidence with real-world data to estimate efficacy and safety. Systematic search on PubM…
New Research Last 24 Months118 records
Rank108.2
Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.
Transplantation and cellular therapy · 2026 · PMID 41525947
In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…
Rank105.6
Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.
Cancer · 2026 · PMID 42487493
BACKGROUND: Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, is a therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after chimeric antigen receptor T-cell therapy. This study summarized efficacy and safety across published cohorts. METHODS: The authors did a systematic review and meta-analysis of loncastuximab tesirine monotherapy in adults with relapsed or refractory DLBCL. They searched PubMed, Embase, and the Cochrane Library from inception to October 25, 2025, plus…
Rank105.5
Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352
INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …
Rank105.1
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
Journal of medical economics · 2026 · PMID 42452801
OBJECTIVE: No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL). METHODS: Following a systematic literature review, individual patient data from trials of zanubrutinib (n = 118) and aggregate data from a pooled analysis of ibrutinib trials (n = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC). RESULTS: After matching selected covariates, statistically significant differences were observed with zanu…
Rank105.1
The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42409674
The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the …
Rank103.0
[Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026 · PMID 42409743
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive type of intestinal T-cell lymphoma. With the application of high-throughput sequencing technologies in recent years, the understanding of this entity has become increasingly comprehensive. The World Health Organization classification of lymphoma now recognizes MEITL as a distinct disease entity. However, the extreme rarity of MEITL poses substantial challenges for clinical diagnosis and management, and patient outcomes re…
Rank100.0
Attributable Fraction of Epstein-Barr Virus in Subtypes of Lymphoma: A Systematic Review and Global Meta-Analysis.
International journal of cancer · 2026 · PMID 41947331
There is evidence for a causal role of Epstein-Barr virus (EBV), a known carcinogen, in an increasing number of lymphoma subtypes, but a systematic evaluation of EBV attributable fraction is lacking. We conducted a systematic review and meta-analysis of EBV prevalence in lymphoma subtypes from 1990 to 2024, stratified by HIV status and geographical region. For each subtype, we calculated pooled prevalence and corresponding 95% confidence intervals (CIs) of EBV, measured by EBV-encoded RNA in situ hybridisation. 307…
Rank98.0
Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis.
Scientific reports · 2025 · PMID 40456850
Confirming the patient benefit of progression-free survival (PFS) in B-cell non-Hodgkin lymphoma (B-NHL) and multiple myeloma (MM) has become increasingly challenging due to the improved outcomes brought by novel therapies. In parallel, the U.S. Food and Drug Administration recommends conducting randomized trials, focusing on evaluating early endpoints to compare study and control arms for accelerated approval (AA). From both the clinical and regulatory perspectives, identifying early surrogate endpoints for PFS is…
Rank95.8
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.
American journal of hematology · 2026 · PMID 42283231
Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun-Pola), with > 2 years of follow-up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun-Pola or R-Pola. Mosunetuzumab was administered subcutaneously with …
Rank95.2
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
The New England journal of medicine · 2026 · PMID 42341302
BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. METHODS: We evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 patients with large B-cell lymphoma and 14 with follicular lymphoma) who had been treated with CTL019 (now called tisagenlecleucel) - autologous T cells expressing CD19-directed, 4-1BB-costimula…
Rank94.9
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.
American journal of hematology · 2026 · PMID 42240061
One quarter of patients with diffuse large B-cell lymphoma (DLBCL) who achieve a complete response following front-line therapy will eventually experience disease relapse. Existing prognostic models use baseline factors to predict outcomes from the start of initial therapy and are not intended for use following completion of treatment. We developed a conditional event-free survival (cEFS) tool that predicts a patient's risk of lymphoma recurrence after completing front-line therapy taking into consideration baselin…
Rank93.2
The surgery for the patients with intestinal non‑Hodgkin lymphomas: a nationwide study.
Annals of medicine · 2026 · PMID 41732903
BACKGROUND: The treatment strategy for intestinal non-Hodgkin lymphoma (NHL) and the role of surgery warrant reevaluation. METHODS: This study analyzed clinical data from a cohort of 12,047 patients diagnosed with intestinal NHL, extracted from the Korean National Health Insurance System database between 2002 and 2021. RESULTS: Among these patients, 3,566 (29.6%) were categorized into the surgery group, while 8,481 (70.4%) were included in the nonsurgery group. Surgery was independently associated with both prolong…
Rank83.2
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
American journal of hematology · 2026 · PMID 42305039
First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. We conducted a phase 2 multicenter trial in the academic and community cancer research united (ACCRU) network, testing a multitargeted 1st line regimen. CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. The primary endpoint was complete metabolic response (CMR) rate. Secondary end…
Rank82.2
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
Oncoimmunology · 2026 · PMID 42415230
Patients with relapsed/refractory follicular lymphoma (R/R FL) often experience multiple disease recurrences with progressively shorter duration of remission. Chemoimmunotherapy (CIT) is commonly used for R/R FL in second-line and later settings but is not curative; novel, improved treatments are needed. Epcoritamab, a CD3 × CD20 bispecific antibody, is approved as monotherapy for R/R FL after ≥ 2 lines of therapy (LOTs) and combined with lenalidomide and rituximab (R2) for R/R FL. Epcoritamab + R2 pivotal data dem…
Rank80.2
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.
Nature communications · 2026 · PMID 42297808
Treatment options for relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) remain limited. In this phase 1b/2 trial (NCT05464433), we evaluated the safety and efficacy of liposomal mitoxantrone (Lipo-MIT) plus anti-PD-1 tislelizumab in this setting. During dose escalation, patients received Lipo-MIT (16 or 20 mg/m2) plus tislelizumab using a 3 + 3 design, followed by dose expansion at the recommended phase 2 dose (RP2D). The primary endpoint of the dose-escalation phase was dose-limiting tox…
Rank78.8
Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 41764665
BACKGROUND: Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment. AIMS: This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions. METHODS: HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospe…
Rank77.0
A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.
Nature communications · 2026 · PMID 42527400
Chimeric antigen receptor (CAR) T-cell therapies are typically administered at high doses to maximize durable clinical responses. However, manufacturing constraints can limit the production of sufficient cells to achieve the intended dose. Although some patients experience durable responses after receiving lower CAR-T cell doses, the mechanisms underlying efficacy at these limited cell numbers remain poorly understood. To address this, we performed deep phenotyping of anti-CD19 CAR-T cell products and their corresp…
Rank75.0
Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.
Annals of medicine · 2026 · PMID 42482660
BACKGROUND: CD5-positive diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype with poor outcomes. Following the approval of Pola-R-CHP in China, this study aimed to evaluate its efficacy as initial therapy for this high-risk population. METHODS: We conducted a multicenter, retrospective study of previously untreated CD5-positive DLBCL patients who received Pola-R-CHP as first-line therapy between April 2023 and February 2025. Treatment response was assessed by PET/CT after 3 cycles and at the end of treat…
Rank74.2
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.
Leukemia & lymphoma · 2026 · PMID 41736495
To contextualize results from the single-arm ELM-2 study of odronextamab (CD20 × CD3 bispecific antibody) in relapsed/refractory (R/R) follicular lymphoma (FL) (N = 128), a post-hoc comparison was conducted versus third-line or later systemic therapies used in the real world (3L + RWST) in FLORA, a multinational, noninterventional study (N = 83; 100 lines of therapy). After weighting, objective response rate (80.5 vs. 52.7%; odds ratio [OR], 3.75 [95% CI, 1.98-7.11]), complete response rate (73.4 vs. 33.6%; OR, 5.3…
Rank73.5
Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.
European journal of nuclear medicine and molecular imaging · 2026 · PMID 42223630
PURPOSE: The clinical use of CD3-CD20-directed bispecific antibodies (BsAbs) has significantly improved outcomes of patients with relapsed/refractory LBCL. However, up to 50% of patients relapse. This study evaluated the prognostic value of longitudinal FDG-PET parameters. METHODS: 58 patients with baseline PET and 45 (78%) with first PET after BsAb initiation were included. Standard PET metrics and Deauville score (DS) were recorded, with percent changes at follow-up defined as ΔPET parameters. Prognostic impact o…
Rank73.0
Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control.
Cancer biology & therapy · 2026 · PMID 42015349
INTRODUCTION: The selection of an optimal maintenance agent in diffuse large B-cell lymphoma (DLBCL) continues to pose a significant clinical challenge. This study aims to evaluate the prognostic impact of maintenance therapy (MT) in DLBCL. METHODS: We conducted a retrospective analysis of data from DLBCL patients undergoing first-line MT at four hospitals in Beijing between January 2019 and August 2024. The REMoDL-B trial database was selected as the control group. RESULTS: The MT group comprised 106 cases and a m…
Rank72.9
Immunohistochemical Expression of p63 and GATA3 in Lymphomas of the Urinary Bladder: A Clinicopathologic Study of a Potential Diagnostic Pitfall.
International journal of surgical pathology · 2026 · PMID 41985039
Urinary bladder lymphomas are rare and may mimic urothelial carcinoma by morphology or unexpected expression of putative "urothelial" markers such as p63/ GATA3, the latter of which has not been thoroughly explored. Herein, we evaluate the clinicopathologic features of bladder lymphomas and assess the incidence of p63/GATA3 expression. A multi-institutional review identified 28 bladder lymphomas. Slides were re-reviewed for lymphoma subtype, growth pattern, urothelial colonization, and concurrent urothelial carcino…
Rank70.2
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42336688
BACKGROUND: Preclinical data support the combination of venetoclax and copanlisib in specific genomic subgroups of diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: In this investigator-initiated, phase I, multicenter trial we aimed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of copanlisib and venetoclax in patients with relapsed/refractory (R/R) DLBCL. Key eligibility criteria included relapse after or noncandidate for autologous stem cell transplantation or chimeri…
Rank68.8
Academic anti CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphomas in real-world clinical practice: a prospective cohort study.
Frontiers in oncology · 2026 · PMID 42539439
BACKGROUND/OBJECTIVE: Chimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed/refractory B-cell lymphomas (r/r BCLs) in recent years. However, high cost of commercial products limits their application in real-world clinical practice. The use of the so-called academic CAR-T cell products can reduce the cost and improve availability and affordability of this therapy option. The aim of the present clinical trial was to assess the efficacy and safety of academic CAR-T cells in r/r BCL …
Rank54.2
Survival and prognostic features of early-stage diffuse large B-cell lymphoma in older adults.
Hematology (Amsterdam, Netherlands) · 2026 · PMID 41922932
BACKGROUND: Early-stage diffuse large B-cell lymphoma (ESDLBCL) in older adults is understudied, and existing prognostic tools such as the stage-adjusted International Prognostic Index (Sa-IPI) may not adequately account for comorbidity and age-related vulnerability. This study evaluated long-term outcomes and developed a simplified prognostic index for patients aged ≥ 60 years with ESDLBCL. METHODS: We retrospectively analyzed adults aged ≥ 60 years with stage I-II DLBCL treated at King Hussein Cancer Center betwe…
Preclinical Research65 records
Rank71.3
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal for immunotherapy of cancer · 2026 · PMID 42413982
BACKGROUND: Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies. GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 epitopes, was shown to induce potent tumor cell killing through enhanced complement-dependent cytotoxicity (CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity (A…
Rank70.2
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42336688
BACKGROUND: Preclinical data support the combination of venetoclax and copanlisib in specific genomic subgroups of diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: In this investigator-initiated, phase I, multicenter trial we aimed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of copanlisib and venetoclax in patients with relapsed/refractory (R/R) DLBCL. Key eligibility criteria included relapse after or noncandidate for autologous stem cell transplantation or chimeri…
Rank68.0
Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Blood advances · 2026 · PMID 41824782
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) typically have a poor prognosis. In preclinical studies, lenalidomide and a Bruton tyrosine kinase (BTK) inhibitor demonstrated synergistic antitumor effects. Zanubrutinib, a next-generation BTK inhibitor, has greater selectivity to minimize off-target binding. BGB-3111-110 was a phase 1 multicenter dose-escalation/-expansion study. Patients with R/R DLBCL received zanubrutinib 160 mg twice daily plus lenalidomide (15, 20, or 25 mg once d…
Rank45.0
A novel spontaneous cytotoxic T-cell lymphoma in chickens.
Veterinary pathology · 2026 · PMID 41645699
Chicken lymphomas are generally classified into three virus-induced tumors: Marek's disease (MD), lymphoid leukosis, and reticuloendotheliosis, with MD being the most common T-cell lymphoma in commercial poultry. In this study, we describe 23 cases of a novel cytotoxic T-cell lymphoma affecting layer chickens aged >1 year in Japan that is distinct from previously known chicken lymphomas. These cases were initially misidentified as MD during routine poultry inspection but were later confirmed as a distinct and novel…
Rank45.0
Auditory brainstem response in pigs: normative data and insights from TPC2 knockout models.
Hearing research · 2026 · PMID 42114217
BACKGROUND: Pigs are increasingly used as translational models for auditory research due to anatomical and physiological similarities with humans. However, normative auditory brainstem response (ABR) parameters in commercial pig breeds remain poorly characterized, limiting their use in hearing research and genetic models. OBJECTIVE: To establish reference ABR values across stimulus intensities in pigs and assess the influence of genotype, age, and sex, including the evaluation of TPC2 knockout (KO) animals. METHODS…
Rank45.0
Central nervous system lymphoma and neurolymphomatosis in equids.
Journal of veterinary internal medicine · 2026 · PMID 42525884
BACKGROUND: Lymphoma affecting the central and peripheral nervous systems in equids is rarely reported. HYPOTHESIS/OBJECTIVES: To describe the clinical presentation, neuroanatomical localization, laboratory and pathologic features, type of lymphoma, and outcome to further current knowledge. ANIMALS: Fourteen equids (13 horses, 1 mule). METHODS: Retrospective study. Medical records from a veterinary teaching hospital were reviewed (1993-2025). The inclusion criteria consisted of a definitive diagnosis of lymphoma of…
Rank45.0
The RNA-binding activity of the Drosophila Brat protein is necessary for viability and mRNA regulation.
RNA biology · 2026 · PMID 42206510
Brain tumor (Brat) is a Drosophila TRIM-NHL protein required for embryogenesis and neural stem cell differentiation. Although structural and biochemical studies established that the Brat NHL domain specifically binds RNA, the in vivo requirement for this activity has not been directly tested. Here, we used structure-guided mutagenesis and genome engineering to determine whether RNA recognition is essential for Brat function during development. The direct interaction between Brat's NHL domain and RNA containing Brat…
Rank45.0
Investigating the pathogenicity of novel non-pathogenic Avibacterium paragallinarum isolates and their protective potential against infectious coryza.
Avian pathology : journal of the W.V.P.A · 2026 · PMID 42210853
Infectious coryza (IC) is a chicken respiratory disease caused by Avibacterium paragallinarum (AP). Recently, multiple naïve-healthy layer (NHL) flocks tested positive for AP by both qPCR and bacterial isolation without clinical signs. Therefore, acquired AP isolates from these NHL flocks were dubbed non-pathogenic AP (npAP). The aim of this study was to investigate the pathogenicity of npAP isolates (Phase I) and their ability to confer protection against IC (Phase II). Seven groups (G1-G7) of 26-week-old laying h…
Rank45.0
Overcoming chemotherapy resistance in diffuse large B-cell lymphoma using multifunctional nanocarriers: current advances and clinical challenges.
Discover nano · 2026 · PMID 42283995
Chemoresistance is a primary challenge in diffuse large B-cell lymphoma (DLBCL) treatment. The review is developed to explore the potential of the nanocarrier strategy to minimize resistance in DLBCL treatment. The application of nanocarriers offers promising solutions to increase the drug delivery, avoid resistance, and minimize off-target delivery. Therapeutic strategies of nanocarriers with targeted delivery, gene-based therapies, and combination therapies are explained in the review. This review further evaluat…
Rank45.0
Pathological characterization of lymphomas with involvement of the alimentary tract in feline leukemia virus-infected cats.
Veterinary pathology · 2026 · PMID 41454673
Lymphoma is a common neoplasm in cats, in which alimentary lymphoma is a common subtype, and it is usually diagnosed in elderly, feline leukemia virus (FeLV)-negative cats. This study aimed to describe the pathological features of lymphoma with involvement of the alimentary tract in FeLV-antigen-positive cats. In a 12-year retrospective study, 32 necropsied and FeLV-infected cats with lymphoma affecting the alimentary tract were identified. Twenty-one cases were multicentric lymphomas with secondary involvement of …
Rank38.4
Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42148884
PURPOSE: Many patients with various cancer types have received immune checkpoint inhibitors (ICI) worldwide since their approval, and novel unexpected complications from their long-term use are apparent. We identified some cases of B-cell lymphoma occurring during PD-1 blockade therapy as such unexpected complications. In this study, we aimed to evaluate the incidence of hematologic malignancies in patients with lung cancer receiving PD-1 blockade therapy and to elucidate the mechanisms underlying the progression o…
Rank35.0
High-grade B-cell lymphoma of the penis in a cat.
The Canadian veterinary journal = La revue veterinaire canadienne · 2026 · PMID 42095159
A 4-year-old neutered male cat was presented with a perineal mass extending over the penis. The mass was surgically excised via perineal urethrostomy. Histopathology confirmed a high-grade B-cell lymphoma confined to the penis and extending microscopically to the prepuce. The cat remained disease free for 6 mo before dying of an unknown cause. To the authors' knowledge, this case may represent the first reported instance of a feline lymphoma clinically confined to the penis. Key clinical message: Penile lymphoma, t…
Rank34.5
LncRNA IRENA promotes peripheral T-cell lymphoma progression through scaffolding ARHGEF1 and FMNL1 to modulate RHOA GTPase/MAPK signaling.
Oncogene · 2026 · PMID 42373804
Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous group of lymphomas, characterized by aggressive behavior and poor outcomes. Investigating the key regulatory long non-coding RNAs (lncRNAs) is helpful to refine current prognostic models and identify novel therapeutic targets in PTCL. Using clinical and transcriptomic data from 172 patients (training cohort) and 36 patients (validation cohort) with newly diagnosed nodal PTCL, this study identified LINC01727 (also known as IRENA) as an independent prognosti…
Rank32.6
Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.
Annals of hematology · 2026 · PMID 42380537
Secondary central nervous system involvement (sCNSi) is a fatal complication of diffuse large B-cell lymphoma (DLBCL), yet its molecular determinants remain poorly understood. To investigate the mechanisms underlying CNS-preferential dissemination, we established an in vivo DLBCL xenograft model using two representative cell lines, OCI-LY19 and Toledo, followed by transcriptomic profiling of lymphoma cells isolated from the brain, peripheral organs, and parental cultures. Transcriptomic analyses revealed gene signa…
Rank32.0
Nuclear receptor subfamily 2 group F member 2 transcriptionally activates 14-3-3 epsilon to promote diffuse large B-cell lymphoma progression.
Cytotechnology · 2026 · PMID 42040327
Diffuse large B-cell lymphoma (DLBCL) represents the most prevalent form of non-Hodgkin lymphoma, distinguished by its aggressive clinical presentation and poor patient outcomes. This study investigated the role of nuclear receptor subfamily 2 group F member 2 (NR2F2) and 14-3-3 epsilon (YWHAE) in DLBCL progression. NR2F2 and YWHAE were highly expressed in DLBCL cell lines and tumor tissues of patients with DLBCL. Elevated expression of both genes correlated with advanced Ann Arbor stage and higher International Pr…
Rank31.4
[Construction of a methionine metabolism-related prognostic signature and the effect of targeting methionine metabolism on diffuse large B-cell lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026 · PMID 42409736
Objective: To construct a prognostic risk model based on methionine metabolism-related genes in diffuse large B-cell lymphoma (DLBCL), investigate its prognostic significance, and clarify the regulatory role of abnormal methionine metabolism in DLBCL progression. Methods: Clinical prognostic information and methionine metabolism-related gene expression data of patients with DLBCL were obtained from the GEO dataset GSE10846. Lasso regression and Cox regression analyses were performed to screen core prognostic genes …
Rank30.0
Transgenic expression of human signal regulatory protein alpha (SIRPα) in BALB/c Rag2null/Jak3null immunodeficient mice enhances human lymphoma xenografts by reducing phagocytosis.
Transgenic research · 2026 · PMID 42289615
The immunodeficient mouse model offers a platform for evaluating therapeutic options in preclinical cancer research by enabling the growth of human xenografts. We previously developed BALB/c Rag2nullJak3null (BRJ), an immunodeficient mouse model useful for cancer studies. However, susceptibility to xenograft acceptance can be increased through signal regulatory protein alpha (SIRPα)-CD47 signaling, also known as the "don't eat me" signal. In this study, we generated BALB/c human-SIRPα BAC transgenic mice and crosse…
Rank30.0
Quantitative longitudinal photoacoustic imaging of vascular oxygenation for therapy response monitoring in Non-Hodgkin lymphoma.
Photoacoustics · 2026 · PMID 42211050
Non-Hodgkin lymphoma (NHL) is clinically heterogeneous and lacks practical tools for repeated, noninvasive monitoring of response. We performed longitudinal photoacoustic imaging (PAI) at five time points in NHL xenografts to quantify Hb, HbO2, HbT, and mSO2, with endpoint histologic and serum validation. Untreated tumors exhibited a natural progression characterized by a progressive decline in mSO2. While Cyclophosphamide (CTX) slowed growth, it induced earlier alterations in oxygenation: mSO2 was higher in the CT…
Rank30.0
NAD+ precursor supplementation reverses CD36-mediated lipid accumulation and ferroptosis to restore antitumor function of NK cells in DLBCL.
Pharmaceutical science advances · 2026 · PMID 41993707
Natural killer (NK) cells play a key role in the standard treatment of diffuse large B-cell lymphoma (DLBCL). However, NK cells in DLBCL patients frequently display an exhausted phenotype, which is associated with poor clinical outcomes. The metabolic mechanisms contributing to this functional impairment remain poorly understood. We assessed degranulation (CD107a), cytokine secretion (IFN-γ, TNF-α), mitochondrial activity, and lipid metabolism in NK cells from DLBCL patients and healthy donors. Dysregulated lipid s…
Rank30.0
Ferroptosis-STING co-activation drives GzmB+CD38+CD8+ T-cell expansion to overcome lymphoma immunosuppression.
Biomaterials · 2026 · PMID 42061111
The immunosuppressive tumor microenvironment (TME) of B-cell lymphoma limits the efficacy of conventional chemotherapy and hampers the full activation of antitumor immunity. Here, we report a tumor cell membrane-camouflaged nanoplatform (CM@HFeS/DOX/MSA-2) that couples ferroptosis amplification with cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway activation to overcome these barriers. The HFeS nanozyme promotes lipid peroxidation (LPO) and reactive oxygen species (ROS) generation, while …
Rank30.0
Synergistic drug repurposing strategy identifies doxorubicin and paclitaxel as potential combination therapy for diffuse large B-cell lymphoma.
Computers in biology and medicine · 2026 · PMID 42235267
PURPOSE: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive subtype of non-Hodgkin lymphoma, characterized by clinical heterogeneity and chemoresistance. About 30% of patients relapse or develop refractory disease despite therapy. This study aimed to identify repurposed antitumor agents with potentially synergistic efficacy against DLBCL through an integrative in silico and in vitro approach. METHODS: DLBCL-associated genes were obtained from DisGeNET and GeneCards, and overlapping genes (OGs) …
Rank30.0
Shikonin suppresses diffuse large B-cell lymphoma progression by inducing ferritinophagy and ferroptosis via lncRNA ADPGK-AS1 downregulation.
Journal of enzyme inhibition and medicinal chemistry · 2026 · PMID 42295078
Shikonin, a natural compound, exhibits antitumor effects in DLBCL, but its mechanism remains unclear. Shikonin's cytotoxicity in DLBCL cells was assessed by MTT assays. Ferroptosis and lipid peroxidation markers were analysed via flow cytometry and biochemical kits. Mechanisms were explored using gene knockdown/overexpression, dual-luciferase assays, RNA pull-down, proteomics, RIP, FISH, and ChIP. Key proteins and genes involved in ferritinophagy and ferroptosis were examined by Western blot, RT-qPCR, and immunoflu…
Rank30.0
Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death.
Blood neoplasia · 2026 · PMID 42376204
Protein arginine methyltransferase 5 (PRMT5), a type II arginine methyltransferase, is overexpressed in several aggressive B-cell malignancies and facilitates cancer cell proliferation. JNJ-64619178, a selective small-molecule inhibitor targeting PRMT5, has previously shown promising preclinical activity across a range of hematological malignancies; however, the clinical activity of JNJ-64619178 monotherapy is limited despite strong target engagement. Therefore, we sought to identify rational combination partners f…
Rank30.0
Glyphosate-based herbicides induce oxidative stress: Insights from human biomarker and in vitro mutagenic studies.
Environmental toxicology and pharmacology · 2026 · PMID 42402262
Glyphosate-based herbicides (GBHs) are widely used and raise concerns about human health risks due to the detection of glyphosate (GLY) in body fluids. Their toxicity remains the subject of ongoing debate, especially regarding their carcinogenic potential, while epidemiological evidence associates GBHs exposure with increased non-Hodgkin lymphoma incidence. This study addresses key gaps by characterizing the kinetic profiles of GLY, its metabolites, and oxidative stress biomarkers in urine from 11 agricultural work…
Rank30.0
Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies.
Molecular therapy. Oncology · 2026 · PMID 42519391
Bruton tyrosine kinase inhibitors (BTKis) have markedly improved the treatment landscape for B cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and Waldenström's macroglobulinemia, since the introduction of the first-in-class BTKi, ibrutinib, a decade ago. Despite their clinical success, the emergence of resistance to BTKis poses a significant therapeutic challenge. The mechanisms of resistance are multifactorial and include genetic mutations, activatio…
Promising Experimental Therapies64 records
Rank107.8
Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.
The Lancet. Haematology · 2026 · PMID 42069410
BACKGROUND: The treatment landscape for relapsed or refractory diffuse large B-cell lymphoma has changed profoundly with the introduction of novel drug classes, some approved solely on the basis of single-arm early-phase trials. We aimed to evaluate antitumour activity and safety outcomes across drug classes in early-phase trials in relapsed or refractory diffuse large B-cell lymphoma since 2000. METHODS: We did a systematic review and meta-analysis of phase 1-2 trials. We searched PubMed, Embase.com, Web of Scienc…
Rank102.6
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41260259
BACKGROUND: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase III randomized study in first-line therapy for DLBCL patients with adjusted-age international prognostic index (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after two cycles of R-CHOP to de-escalate treatment duration. PATIENTS AND METHODS: LNH2009-1B study is a two-arm, open-label, multicen…
Rank99.9
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Lancet (London, England) · 2026 · PMID 42134356
BACKGROUND: Adding ibrutinib to standard, first-line immunochemotherapy improves failure-free survival in adult patients aged 18-65 years with mantle cell lymphoma, according to the first results from the TRIANGLE trial. With prolonged follow-up, we investigated whether the addition of autologous stem-cell transplantation (ASCT) to an ibrutinib-containing regimen improves failure-free survival, and evaluated effects on overall survival. METHODS: We conducted a three-arm, randomised, open-label, phase 3 superiority …
Rank98.2
Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.
International journal of clinical oncology · 2026 · PMID 41989666
BACKGROUND: This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma. METHODS: In this double-blind, multicenter, randomized phase II study, 40 patients received hydroxyzine or bepotastine with acetaminophen 30 min before rituximab infusion. Primary endpoint was incidence of ≥ grade 2 IRRs based on the National…
Rank98.1
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.
The Lancet. Haematology · 2026 · PMID 42285113
BACKGROUND: Anthracycline-free regimens are needed for older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We aim to evaluate the efficacy and safety of fixed-duration epcoritamab monotherapy versus epcoritamab with lenalidomide in this patient population. METHODS: This open-label, multicentre, randomised, phase 2 trial was conducted at 44 hospitals across 11 countries in Europe and Asia. Patients had newly diagnosed, histologically confirmed CD20-positive large B-cell lymphoma, were ineligible…
Rank95.8
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.
American journal of hematology · 2026 · PMID 42283231
Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun-Pola), with > 2 years of follow-up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun-Pola or R-Pola. Mosunetuzumab was administered subcutaneously with …
Rank95.2
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
The New England journal of medicine · 2026 · PMID 42341302
BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. METHODS: We evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 patients with large B-cell lymphoma and 14 with follicular lymphoma) who had been treated with CTL019 (now called tisagenlecleucel) - autologous T cells expressing CD19-directed, 4-1BB-costimula…
Rank83.2
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
American journal of hematology · 2026 · PMID 42305039
First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. We conducted a phase 2 multicenter trial in the academic and community cancer research united (ACCRU) network, testing a multitargeted 1st line regimen. CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. The primary endpoint was complete metabolic response (CMR) rate. Secondary end…
Rank83.1
Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.
Annals of hematology · 2026 · PMID 42209885
Peripheral T-cell lymphomas (PTCLs) are rare, aggressive malignancies with poor outcomes, particularly in the relapsed or refractory (R/R) setting. Given the frequent CD38 expression in PTCLs, this multicenter, open-label, single-arm phase II study (FIL_Dara-GDP; EudraCT 2018-002644-91) evaluated daratumumab, an anti-CD38 monoclonal antibody, combined with gemcitabine, dexamethasone, and cisplatin (D-GDP) in CD38-positive systemic PTCLs. The trial aimed to achieve a complete response (CR) rate of ≥ 40% after four c…
Rank83.0
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26).
Blood cancer journal · 2026 · PMID 41844573
Patients with peripheral T cell lymphoma (PTCL) who achieved tumor response with first-line standard therapy were at high risk of disease relapse. We explored golidocitinib (150 mg once daily) as maintenance therapy for this group of patients (JACKPOT26, NCT06511869). This study included two cohorts: patients achieving a complete response (Cohort 1 (CR), N = 30) and a partial response (Cohort 2 (PR), N = 18) during induction stage. All enrolled patients were transplant ineligible or did not have a transplant plan. …
Rank82.2
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
Oncoimmunology · 2026 · PMID 42415230
Patients with relapsed/refractory follicular lymphoma (R/R FL) often experience multiple disease recurrences with progressively shorter duration of remission. Chemoimmunotherapy (CIT) is commonly used for R/R FL in second-line and later settings but is not curative; novel, improved treatments are needed. Epcoritamab, a CD3 × CD20 bispecific antibody, is approved as monotherapy for R/R FL after ≥ 2 lines of therapy (LOTs) and combined with lenalidomide and rituximab (R2) for R/R FL. Epcoritamab + R2 pivotal data dem…
Rank81.2
Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42018969
PURPOSE: Peripheral T-cell lymphomas (PTCLs) are rare, heterogeneous, aggressive lymphomas. Five-year overall survival (OS) remains approximately 30%-40%, and most patients will develop relapsed or refractory (R/R) disease. Duvelisib is an oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ and PI3K-γ isoforms. Here, we report on the final analysis of the phase II PRIMO trial (ClinicalTrials.gov identifier: NCT03372057; Secura Bio, Inc) evaluating duvelisib monotherapy in R/R PTCL. METHODS: PRIMO was cond…
Rank80.9
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
American journal of hematology · 2026 · PMID 41862428
Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharmacokinetics (PK), efficacy, and safety of mosunetuzumab SC (N = 94; median follow-up: 26.1 months) at the recommended Phase 2 dose (Cycle [C]1 Day [D]1: 5 mg; C1D8 and D15, and C2D1 onwards: 45 mg) in patients with R/R FL after ≥ 2 pri…
Rank80.9
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.
American journal of hematology · 2026 · PMID 41804087
In this single-arm, single-center, registrational phase 2 trial, tandem CD19/CD20 chimeric antigen receptor (CAR) T cell (TanCAR7) therapy showed promising efficacy and safety in patients with relapsed/refractory non-Hodgkin's lymphoma (r/r NHL). Here, we report 5-year follow-up results, including assessments of durable response, survival, and safety. We also investigated risk factors and biomarkers associated with treatment resistance or relapse and evaluated salvage therapies after CAR-T cell failure. Among 87 pa…
Rank80.9
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.
Signal transduction and targeted therapy · 2026 · PMID 42036411
This phase 2, single-arm, multi-center study (NCT03934567) evaluates the efficacy and safety of abexinostat, a histone deacetylase inhibitor, in patients with relapsed or refractory (r/r) follicular lymphoma (FL). Eligible participants had previously received a minimum of two systemic treatment lines, such as cytotoxic agents and/or anti-CD20 monoclonal antibodies. Participants received abexinostat 80 mg oral twice daily on a schedule of seven days on and seven days off, within 28-day cycles, continuing until unacc…
Rank80.6
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.
Lancet (London, England) · 2026 · PMID 41692020
BACKGROUND: Effective treatments with deep and durable responses for relapsed or refractory marginal zone lymphoma (MZL) are lacking. The objective of the primary analysis from the MZL cohort of TRANSCEND FL was to evaluate the efficacy and safety of the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel. METHODS: In this phase 2, single-arm, multicohort study, patients from 30 sites in the USA, Canada, Europe, and Japan with relapsed or refractory MZL who had at least two previou…
Rank80.6
Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.
Blood advances · 2026 · PMID 41512176
The phase 2 ALYCANTE trial aimed to evaluate the investigator-assessed complete metabolic response at 3 months from the axicabtagene ciloleucel (axi-cel) infusion as a primary end point in patients with high-risk relapsed/refractory large B-cell lymphoma who are ineligible for autologous stem cell transplantation (ASCT). This study showed a significant improvement in complete metabolic response rate at 3 months based on historical controls. This study reports the health-related quality of life (HRQoL) results as a …
Rank80.2
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.
Nature communications · 2026 · PMID 42297808
Treatment options for relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) remain limited. In this phase 1b/2 trial (NCT05464433), we evaluated the safety and efficacy of liposomal mitoxantrone (Lipo-MIT) plus anti-PD-1 tislelizumab in this setting. During dose escalation, patients received Lipo-MIT (16 or 20 mg/m2) plus tislelizumab using a 3 + 3 design, followed by dose expansion at the recommended phase 2 dose (RP2D). The primary endpoint of the dose-escalation phase was dose-limiting tox…
Rank80.1
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
Blood advances · 2026 · PMID 41544219
Marginal zone lymphoma (MZL) is a group of indolent B-cell malignancies with a remitting and relapsing course. For systemic disease, available first-line therapies include anti-CD20 antibody as monotherapy or in combination with chemotherapy (chemoimmunotherapy), with second-line options including covalent Bruton tyrosine kinase inhibitors (cBTKi). However, management of relapsed and refractory (R/R) MZL remains challenging. Pirtobrutinib, a highly selective, noncovalent BTKi has shown promising efficacy and tolera…
Rank80.1
An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.
Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42209393
INTRODUCTION: Management of relapsed mantle cell lymphoma (MCL) has included Bruton's tyrosine kinase (BTK) inhibitors for more than 10 years, but finding an optimal combination partner that meaningfully improves outcomes while limiting toxicity has been difficult. We conducted a phase 1/2 trial of ibrutinib and the proteasome inhibitor, ixazomib, in patients with relapsed/refractory MCL. PATIENTS AND METHODS: Patients and Methods: The primary endpoint for the phase 1 study was to determine the recommended phase 2 …
Rank80.1
Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41231109
PURPOSE: Chimeric antigen receptor (CAR) T-cell therapies have improved outcomes in patients with relapsed/refractory large B-cell lymphoma (LBCL). However, up to two thirds of these patients do not maintain long-term responses. The phase 1/2 ZUMA-6 study investigated the feasibility of combining the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel) with the PD-L1 inhibitor atezolizumab as a potential approach to increase treatment efficacy while maintaining acceptable safety. PATIENTS AND METHODS:…
Rank80.0
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41427952
PURPOSE: An unmet treatment need remains for relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), including the follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL) subtypes. The PI3K/AKT/mTOR pathway is dysregulated and associated with poor prognosis in NHL. The AKT inhibitor capivasertib has preclinical activity in hematologic malignancy models. PATIENTS AND METHODS: NCT05008055 was a modular, open-label, multicenter phase II study that examined oral capivasertib monotherapy in …
Rank80.0
Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.
Nature communications · 2026 · PMID 42026073
Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at…
Rank80.0
Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal for immunotherapy of cancer · 2026 · PMID 42144261
BACKGROUND: Relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma (B-NHL) remains a major therapeutic challenge despite CD19-directed chimeric antigen receptor (CAR) T-cell therapies, with treatment failure often driven by antigen escape and limited CAR-T persistence. Dual targeting of CD19 and CD20 may mitigate antigen loss. We conducted an expanded phase I/II study of bispecific CD19/20 CAR-T cells and incorporated spatially resolved single-cell transcriptomics to evaluate tumor-intrinsic and microenvironmen…
Rank79.7
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.
Nature communications · 2026 · PMID 41986386
Despite the success of CAR T therapy in non-Hodgkin lymphoma (NHL), recurrence remains challenging. Previously, we showed that ex vivo priming with decitabine (DAC) enhances CAR T persistence and efficacy. Here, we report on an open-label non-randomised phase I/II trial (NCT04697940) evaluating DAC-primed CD19/CD20 dual-targeted CAR T cells (dCAR T) in 23 patients with relapsed or refractory NHL. Primary endpoints are safety and dose-toxicity for phase I, and overall response rate and complete response rate (CRR) f…
Prospective Cohort Studies61 records
Rank108.2
Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.
Transplantation and cellular therapy · 2026 · PMID 41525947
In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…
Rank102.6
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41260259
BACKGROUND: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase III randomized study in first-line therapy for DLBCL patients with adjusted-age international prognostic index (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after two cycles of R-CHOP to de-escalate treatment duration. PATIENTS AND METHODS: LNH2009-1B study is a two-arm, open-label, multicen…
Rank101.0
The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.
Hematological oncology · 2026 · PMID 42062177
The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B-cell lymphoma (DLBCL). Treatment consisted of six cycles of R-CHOP + 2xR or DA-EPOCH-R + 2xR. Patients with intermediate or high-risk CNS International Prognostic Index (CNS-IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m2 i.v. (arm A) or 6 doses of MTX 12 mg i.t. (arm B). P…
Rank99.6
A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465
BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…
Rank95.4
Endoscopic ultrasound (EUS) elastography-guided fine-needle aspiration cytology (FNAC) versus conventional EUS FNAC for solid pancreatic lesions: A pilot randomized trial.
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025 · PMID 39230660
BACKGROUND: Endoscopic ultrasound guided fine-needle aspiration (EUS FNA) is the first-line modality to diagnose suspected solid pancreatic malignant lesions. Elastography-guided FNA has been shown to improve the diagnostic yield of EUS FNA but prospective studies are limited. The aim of the study was to compare diagnostic accuracy, sensitivity and specificity of conventional and elastography-guided EUS FNA in patients with suspected malignant pancreatic solid masses. METHODS: Patients with suspected malignant soli…
Rank95.3
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41329901
PURPOSE: Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed. METHODS: The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,48…
Rank94.0
Vegetarian diets and cancer risk: pooled analysis of 1.8 million women and men in nine prospective studies on three continents.
British journal of cancer · 2026 · PMID 41748939
BACKGROUND: Vegetarian diets might influence cancer risk. METHODS: We studied 1,645,555 meat eaters, 57,016 poultry eaters, 42,910 pescatarians, 63,147 vegetarians and 8849 vegans in 9 cohorts (UK, US, Taiwan, India). After a median 16 years follow-up, incident cancers were: 4504 mouth and pharynx, 1308 oesophagus (squamous cell), 2105 oesophagus (adenocarcinoma), 3578 stomach, 30,528 colorectum, 2970 liver, 8030 pancreas, 3077 lung (never smokers), 61,368 breast, 11,220 endometrium, 8076 ovary, 45,946 prostate, 71…
Rank80.0
Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.
Nature communications · 2026 · PMID 42026073
Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at…
Rank79.0
Serum triglyceride and apolipoprotein A1 as dynamic biomarkers in extranodal NK/T-cell lymphoma (ENKTL): A multicenter retrospective and prospective validation study.
Annals of hematology · 2025 · PMID 41242997
Extranodal NK/T-cell lymphoma (ENKTL), an aggressive non-Hodgkin lymphoma subtype, exhibits understudied links between lipid metabolism and clinical outcomes. We analyzed 1,017 patients newly diagnosed with ENKTL and matched controls, with longitudinal LC-MS-based metabolomic profiling (n = 29) and pretreatment tumor transcriptomic analysis (n = 65). Multivariable Cox models evaluated lipid biomarkers. Patients with ENKTL showed significantly elevated triglycerides (TG) and reduced apolipoprotein A1 (ApoA1) vs. con…
Rank78.8
Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 41764665
BACKGROUND: Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment. AIMS: This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions. METHODS: HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospe…
Rank78.1
Significant Impact of Treatment Abandonment on Survival of Children With "Common and Curable" GICC Index Cancers in Sub-Saharan Africa-A Multicenter Prospective CANCaRe Africa Study.
Pediatric blood & cancer · 2025 · PMID 40899378
BACKGROUND: The World Health Organization Global Initiative for Childhood Cancer (GICC) targets a global survival rate of 60% for childhood cancer, focusing initially on six common, curable cancers. This study describes survival rates of five of these cancers in sub-Saharan Africa and assesses the impact of treatment abandonment (TxA). METHODS: This multicenter, prospective, observational cohort study included newly diagnosed children (<16 years) with Burkitt lymphoma (BL), acute lymphoblastic leukemia (ALL), Wilms…
Rank76.8
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.
Blood advances · 2026 · PMID 41979332
Primary mediastinal large B-cell lymphoma (PMBL) achieves excellent outcomes with dose-dense immunochemotherapy, yet response assessment by positron emission tomography (PET) remains limited. In this prospective multicenter observational study, we evaluated the clinical relevance of circulating tumor DNA (ctDNA) minimal residual disease (MRD) in patients with newly diagnosed PMBL and assessed whether MRD enhances outcome discrimination beyond PET. Plasma and PET images were collected at baseline and after 2 and 4 c…
Rank76.4
The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · PMID 41273402
PURPOSE: We performed post-marketing surveillance of the safety and effectiveness of 3.6 mg pegfilgrastim to prevent chemotherapy-induced febrile neutropenia (FN) in real-world conditions in Japan. METHODS: Patients were registered between June 2015 and May 2017 and followed prospectively. Pegfilgrastim was administered once every chemotherapy cycle (maximum 6 cycles). Use of pegfilgrastim, safety, and effectiveness in reducing FN were evaluated. RESULTS: From 300 institutions, 1,597 patients were registered and 1,…
Rank75.6
De Novo Cancer in Liver Transplant Patients With HIV Infection: A Multicenter Nationwide Cohort Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · PMID 41989878
BACKGROUND: Patients with human immunodeficiency virus (HIV) infection have been gradually accepted as solid organ transplant recipients, although there is still concern that the burden of immunosuppression and HIV infection could increase the risk of post-transplant cancer. METHODS: The risk of de novo cancer was evaluated in a prospective cohort of 272 HIV-positive and 816 matched HIV-negative liver transplant recipients in Spain (2002-2012). All tumors, except hepatocellular carcinoma recurrence and non-melanoma…
Rank74.6
Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.
Leukemia · 2026 · PMID 41981103
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an elevated risk of hematologic and solid cancers. We performed a prospective cohort study, including 63690 patients with a first diagnosis of primary cancer in the UK Biobank during 2006 to 2022, to investigate the association of pre-diagnostic CHIP with future risk of second cancers. Cox regression was employed to assess the association between pre-diagnostic CHIP and risk of developing second cancer among patients with primary cancer. We i…
Rank74.5
Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.
The Lancet. Haematology · 2026 · PMID 42285114
BACKGROUND: Chimeric antigen receptor (CAR) T cells have shown considerable promise in treating patients with haematological malignancies. We aimed to investigate short-term patient-reported symptomatic adverse events in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy and compare them with those reported by their treating physicians. We also examined factors predicting overall short-term burden of therapy. METHODS: This was a prospective, observational, multicentre study enrolling patients…
Rank74.4
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41428995
PURPOSE: Circulating tumor DNA (ctDNA) is emerging as a promising tool to monitor treatment response in large B-cell lymphoma (LBCL). Tracking tumor-specific phased variants (PVs) allows ultrasensitive detection of minimal residual disease (MRD) that may enhance the accuracy of response assessment. Previous studies have been constrained by small cohort size, retrospective design, or assays limited to a single commercial provider. PATIENTS AND METHODS: DIRECT was a prospective, multisite study evaluating the utility…
Rank74.0
Vulnerability to Infections and Secondary Immunodeficiencies in Patients with Non-Hodgkin's Lymphomas Starting Anti-CD20 Antibody-Containing Therapies.
Oncology research and treatment · 2026 · PMID 41697935
INTRODUCTION: Only limited data exist about immune status, secondary immunodeficiencies, and vulnerability to infections in correlation to anti-CD20 antibody-containing therapies (CD20CT) in non-Hodgkin's lymphoma (NHL) patients. Morbidity, mortality, and hospitalisation rates in routine care are not known. METHODS: Multicentre prospective observational study of 101 unselected NHL patients who were about to start CD20CT between April, 2021 and December, 2023 in nine haematology/oncology group practices in Germany. …
Rank74.0
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.
Journal for immunotherapy of cancer · 2022 · PMID 35750419
UNLABELLED: Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-Hodgkin's lymphomas, carry a worse prognosis for most subtypes when compared with their B-cell counterparts. Despite recent approval of newer therapies, the outlook for patients with relapsed/refractory (RR) PTCL remains poor and new treatment strategies are clearly needed. Targeting the profoundly immunosuppressive tumor microenvironment in PTCL is one such approach. To determine whether immune checkpoint blockade target…
Rank73.0
Incidence of lymphomas in a nationwide prospective cohort study of breast-implanted women.
Breast (Edinburgh, Scotland) · 2026 · PMID 42090861
BACKGROUND: The true incidence of Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare cancer associated with textured breast implants, remains uncertain due to limitations of implant exposure data and long-term follow-up. Concerns regarding other implant-associated malignancies are growing. This study aimed to determine the incidence of BIA-ALCL, non-BIA-ALCL lymphoma, and Breast Implant Associated-Squamous Cell Carcinoma (BIA-SCC). METHODS: 10,339 women with a first-time breast implantation…
Rank72.0
Patient-Reported Outcomes of CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients and Their Impact on Survival.
Transplantation and cellular therapy · 2026 · PMID 41016707
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy has significantly improved outcomes for patients with non-Hodgkin lymphoma (NHL), but not all patients achieve long-term remission, and serious side effects are common. Predicting prognosis after CAR-T remains challenging. Patient-reported outcomes (PRO), such as health-related quality of life (HRQoL), provide valuable insights into the impact of the disease and treatment on patients' wellbeing. However, real-world PRO data are limited and it is unknown w…
Rank71.9
Association of Pre-Diagnostic Clonal Hematopoiesis of Indeterminate Potential With Prognosis Among Patients With Cancer.
American journal of hematology · 2025 · PMID 40787700
Clonal hematopoiesis of indeterminate potential (CHIP) might impair prognosis of several cancer types. Since previous studies predominantly focused on CHIP after cancer diagnosis, little is known about whether CHIP prior to cancer diagnosis predicts outcome. We performed a prospective cohort study, including 63 486 patients with cancer during 2006 to 2022 in the UK Biobank, to evaluate the association between pre-diagnostic CHIP and survival of cancer patients. Hazard ratios (HR) and 95% confidence intervals (CI) w…
Rank70.0
68 Ga-pentixafor PET/CT Indicates Inconsistent Response With Monoclonal Protein-based Response Criteria in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Patients Treated With Bruton Tyrosine Kinase Inhibitors.
Clinical nuclear medicine · 2026 · PMID 42113823
BACKGROUND: Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is a rare, indolent non-Hodgkin lymphoma. Bruton tyrosine kinase inhibitors (BTKis) have been widely used for the treatment of WM/LPL. The objective of this study is to evaluate the response assessed by 68 Ga-pentixafor PET/CT in patients with WM/LPL treated with either BTKi or chemoimmunotherapy. PATIENTS AND METHODS: This is a post hoc analysis of the data from our prospective cohort study. A total of 33 patients with newly diagnosed or…
Rank69.8
MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma.
Cancer research communications · 2026 · PMID 42081255
UNLABELLED: Glioblastoma (GBM), isocitrate dehydrogenase wild-type (IDHwt) and central nervous system diffuse large B-cell lymphoma (CNS-DLBCL) are aggressive brain tumors with overlapping MRI features, yet distinct treatment approaches. Noninvasive tools are needed to aid in differential diagnosis. Deep learning on T1 postcontrast and T2-weighted MRI sequences were used to differentiate GBM and CNS-DLBCL. A three-stage temporal study design was utilized. Model development was performed on 146 patients with CNS-DLB…
Rank69.4
Patterns and pitfalls: Dermoscopic differentiation of early-stage mycosis fungoides, atopic dermatitis, and psoriasis.
Journal of the American Academy of Dermatology · 2026 · PMID 41419138
BACKGROUND: Mycosis fungoides (MF), psoriasis (Pso), and atopic dermatitis (AD) may present with overlapping clinical features, which may lead to delayed diagnosis. Dermoscopy, including ultraviolet (UV) mode, can help distinguish disease-specific patterns. OBJECTIVE: To compare dermoscopic and UV features of early-stage MF, Pso, and AD. METHODS: In this prospective cohort study, 159 patients (MF: 55, Pso: 53, AD: 51) were examined with dermoscopy and UV mode. Vascular patterns, scale features, background color, st…
Quality Of Life61 records
Rank107.8
Understanding the factors influencing quality of life among survivors of Non-Hodgkin lymphoma after completing primary treatment: a systematic review.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 41774244
PURPOSE: To evaluate and synthesize the existing evidence on factors influencing the quality of life (QoL) of non-Hodgkin lymphoma (NHL) survivors and the impact of these factors on their QoL. METHODS: A systematic review was conducted following PRISMA guidelines, with searches in CINAHL, MEDLINE, PubMed, ScienceDirect, Scopus, and Web of Science. Studies published between 2014 and 2025 were included if they were original English-language research involving adult (age ≥ 18 years) NHL survivors and focused on factor…
Rank100.0
Effects of physical activity and exercise interventions in health-related variables in Hodgkin's and non-Hodgkin's lymphoma patients during clinical treatment: a systematic review and single-arm meta-analysis.
The Journal of sports medicine and physical fitness · 2026 · PMID 41757629
INTRODUCTION: Cancer-related fatigue and reduced health-related quality of life (HRQOL) are common among lymphoma patients undergoing treatment. Exercise may be safe and feasible for individuals with hematological malignancies, with potential benefits in mitigating treatment-related toxicity and enhancing treatment tolerance. This systematic review and meta-analysis aimed to evaluate the effects of exercise interventions on health-related outcomes such as HRQOL, muscle strength, cardiorespiratory fitness (CRF), fat…
Rank100.0
Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.
Blood advances · 2026 · PMID 41351516
The incidence of diffuse large B-cell lymphoma (DLBCL) increases with older age. Thus, subgroup reporting for older adults in clinical trials is necessary to determine the relevance of novel therapy outcomes to this vulnerable population. This study assessed subgroup reporting of older adults (aged ≥65 years) enrolled in US Food and Drug Administration and European Medicines Agency registration trials for DLBCL between 2017 and 2023. Clinical efficacy end points for each trial were extracted from ClinicalTrials.gov…
Rank99.6
A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465
BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…
Rank98.0
Protocol for a mixed-methods modified Delphi study for the development of a core domain set to assess the health-related quality of life of patients with mycosis fungoides and Sézary syndrome in clinical trials.
BMJ open · 2026 · PMID 41651511
INTRODUCTION: Cutaneous T cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas that primarily affects the skin and can mimic inflammatory dermatoses. Unlike many skin diseases, CTCL can lead to disabling symptoms, and advanced CTCL can even be fatal. Early studies investigating health-related quality of life (HRQOL) in patients with mycosis fungoides (MF) and Sézary syndrome (SS), common subtypes of CTCL, demonstrated significant impairment across numerous domains. The aim of this current study is to develop a …
Rank97.9
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
Blood · 2026 · PMID 40997297
Diffuse large B-cell lymphoma (DLBCL) poses a challenge in hematology given its varied symptoms, and the complex interplay between disease and treatment effects on health-related quality of life (HRQoL). The phase 3 POLARIX study demonstrated superior progression-free survival and a similar safety profile with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously unt…
Rank97.8
Cost-utility Analysis of R-CHOP vs CHOP in Patients with Non-Hodgkin's Lymphoma: A Systematic Review.
Acta medica Philippina · 2026 · PMID 41835908
BACKGROUND AND OBJECTIVES: Non-Hodgkin Lymphoma (NHL) ranks 11th in cancer incidence and mortality in the Philippines with the combination chemotherapy composed of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) being commonly used as treatment. However, the addition of Rituximab to CHOP (R-CHOP) has been shown to exhibit higher response rates and longer remissions, potentially improving quality of life. Currently, there is conflicting evidence on the cost-utility of CHOP versus R-CHOP. The study …
Rank97.4
Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.
Journal of patient-reported outcomes · 2026 · PMID 42329537
INTRODUCTION: Three patient-reported outcome (PRO) measures specific to lymphoma symptoms were previously defined using mixed-methods research, comprising questions from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and Item Library (IL): measures of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Symptoms, Mantle Cell Lymphoma (MCL) Symptoms, and an Expanded Fatigue measure. The objective of this study was to assess ps…
Rank96.6
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · PMID 41037766
PURPOSE: Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell-engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate (Mosun-Pola), represents a novel fixed-duration outpatient therapy. METHODS: In the phase III SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem-cell transplant were randomly assigned (2:1) to receive Mosun-Po…
Rank89.5
Exercise During Chemotherapy Treatment as an Adjuvant Programme in Patients With Lymphoma (EDONOLA): Study Protocol for a Randomised Controlled Trial.
Cancer control : journal of the Moffitt Cancer Center · 2026 · PMID 42343877
IntroductionLymphomas are a heterogeneous group of haematological malignancies commonly treated with chemotherapy. Hodgkin lymphoma predominantly affects younger adults, while Non-Hodgkin lymphoma is more prevalent among older adults. Although survival outcomes have improved, treatment-related cardiovascular, musculoskeletal, and functional adverse effects contributing to fatigue, reduced cardiorespiratory fitness (CRF), diminished quality of life (QoL), and increased frailty risk, remain, particularly among older …
Rank88.6
A Parent-Delivered Foot Bath Intervention for Chemotherapy-Related Fatigue in Children with Cancer: A Family-Centered Randomized Controlled Trial.
Children (Basel, Switzerland) · 2026 · PMID 42509946
Background/Objectives: Chemotherapy-related fatigue (CRF) affects 50-80% of children receiving chemotherapy and significantly impairs quality of life. Despite the family-centered care framework guiding pediatric oncology practice, evidence on parent-delivered, home-based non-pharmacological interventions for CRF remains limited. This study aimed to evaluate the effect of a parent-delivered warm-water foot bath on CRF in children aged 7-12 years undergoing chemotherapy. Methods: A two-arm parallel randomized control…
Rank85.0
Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review.
Journal of patient-reported outcomes · 2026 · PMID 41606262
BACKGROUND: Non-Hodgkin lymphoma (NHL) constitutes a biologically and clinically heterogeneous group of lymphoid malignancies, with varying prognoses and treatment aims between indolent and aggressive subtypes. While survival outcomes remain key efficacy measures, they insufficiently capture the impact of disease and treatment on daily physical and psychosocial functioning, as well as quality of life (QoL). OBJECTIVES: To characterize the use and reporting of patient-reported outcomes (PROs) in adult NHL randomized…
Rank80.6
Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.
Blood advances · 2026 · PMID 41512176
The phase 2 ALYCANTE trial aimed to evaluate the investigator-assessed complete metabolic response at 3 months from the axicabtagene ciloleucel (axi-cel) infusion as a primary end point in patients with high-risk relapsed/refractory large B-cell lymphoma who are ineligible for autologous stem cell transplantation (ASCT). This study showed a significant improvement in complete metabolic response rate at 3 months based on historical controls. This study reports the health-related quality of life (HRQoL) results as a …
Rank78.8
Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 41764665
BACKGROUND: Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment. AIMS: This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions. METHODS: HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospe…
Rank75.5
Age-related histopathological and immunophenotypic variations in early-stage mycosis fungoides: a multicentre retrospective study in Türkiye.
BMJ open · 2026 · PMID 41985965
OBJECTIVES: Early-stage mycosis fungoides (MF) is diagnostically challenging due to overlap with inflammatory dermatoses. Age-related immunological and cutaneous changes may modify histopathological presentation. We aimed to compare clinical, histopathological and immunophenotypic features of early-stage MF between geriatric and non-geriatric patients. DESIGN: Multicentre retrospective cross-sectional study. SETTING: Dermatology departments of tertiary centres in Türkiye. PARTICIPANTS: A total of 541 patients diagn…
Rank74.5
Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.
The Lancet. Haematology · 2026 · PMID 42285114
BACKGROUND: Chimeric antigen receptor (CAR) T cells have shown considerable promise in treating patients with haematological malignancies. We aimed to investigate short-term patient-reported symptomatic adverse events in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy and compare them with those reported by their treating physicians. We also examined factors predicting overall short-term burden of therapy. METHODS: This was a prospective, observational, multicentre study enrolling patients…
Rank72.0
Patient-Reported Outcomes of CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients and Their Impact on Survival.
Transplantation and cellular therapy · 2026 · PMID 41016707
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy has significantly improved outcomes for patients with non-Hodgkin lymphoma (NHL), but not all patients achieve long-term remission, and serious side effects are common. Predicting prognosis after CAR-T remains challenging. Patient-reported outcomes (PRO), such as health-related quality of life (HRQoL), provide valuable insights into the impact of the disease and treatment on patients' wellbeing. However, real-world PRO data are limited and it is unknown w…
Rank60.0
Psychological Distress, Symptom Burden and Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome.
Acta dermato-venereologica · 2026 · PMID 42454691
Mycosis fungoides (MF) and Sézary syndrome (SS) are rare cutaneous lymphomas with limited data on psychological burden. This observational, cross sectional questionnaire study assessed symptom burden, psychological distress and quality of life (QoL) in patients with MF and SS in Western Sweden and compared outcomes with psoriasis. Sixty patients were included, 80% with early-stage disease. Most reported minimal depression, anxiety and QoL impairment. Moderate-to-severe depression occurred in 36% of advanced disease…
Rank53.2
Pre-Pectoral Breast Reconstruction after Mastectomy: Current Evidence, Knowledge Gaps, and Rationale for the I-PREPARE EUBREAST-11R Trial.
Breast care (Basel, Switzerland) · 2026 · PMID 42383235
INTRODUCTION: Pre-pectoral implant-based breast reconstruction (IBR) has emerged as a promising alternative to conventional subpectoral approaches following nipple- or skin-sparing mastectomy. However, long-term oncological safety, complication profiles, and outcomes in specific subgroups, such as patients receiving radiation therapy (RT), remain under investigation. Contemporary evidence is mainly derived from retrospective studies with limited follow-up, reporting heterogeneous results. The I-PREPARE trial (EUBRE…
Rank51.0
Exploratory association of muscle and adipose tissue indices with clinical outcomes in aggressive lymphomas.
Cancer · 2026 · PMID 41669999
BACKGROUND: Muscle and adipose tissue quantified on computed tomography (CT) are associated with overall survival (OS), toxicity, and quality of life (QOL) in solid tumor malignancies. This study sought to evaluate the association of body composition with outcomes in older adult aggressive non-Hodgkin lymphoma (aNHL). METHODS: The authors conducted a longitudinal study of 105 adults ≥65 years old with aNHL receiving chemoimmunotherapy. They performed body composition analysis on pretreatment CTs (third lumbar verte…
Rank50.7
Low musculoskeletal health literacy is associated with inferior outcomes in total shoulder arthroplasty.
JSES international · 2026 · PMID 42063489
BACKGROUND: The aim of this study was to investigate the impact of musculoskeletal (MSK) health literacy on clinical outcomes and patient satisfaction following total shoulder arthroplasty (TSA). We hypothesized that low MSK health literacy score would be associated with inferior clinical outcomes and lower patient satisfaction rates. METHODS: A retrospective cohort study was conducted at a tertiary care center. Patients between 6 months and 9 years post-operative following shoulder arthroplasty, both anatomic tota…
Rank50.5
Longitudinal Patient-Reported Symptom Change Patterns and Prediction of Future Health-Related Quality of Life in Childhood Cancer Survivors: A Machine Learning Approach from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
Cancers · 2026 · PMID 42192908
BACKGROUND: Adult survivors of childhood cancer face a significant risk for treatment-related late effects that may impair health-related quality of life (HRQoL). Incorporating longitudinal changes in patient-reported symptoms beyond treatment-based risk factors may enhance the prediction of HRQoL. METHODS: Survivors (n = 576) dually enrolled in the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study reported 37 symptoms across 10 domains at three time points over 20 years to ascertain longitudinal s…
Rank50.0
Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population.
Journal of medical economics · 2026 · PMID 41705966
AIM: Conventional therapies in Japan for relapsed or refractory large B-cell lymphoma (r/r LBCL) require intravenous infusion (IV), while epcoritamab is administered subcutaneously. Despite the expected quality of life (QOL) improvement from reduced drug administration burden, limited data exists on QOL for common r/r LBCL treatment modalities. This study aimed to estimate the impact of drug administration on QOL (i.e. process utility) across treatments for r/r LBCL using responses from the Japanese general populat…
Rank49.6
Psychosocial burden and coping strategies among lymphoma patients: a nurse-led hematology care approach.
Frontiers in psychology · 2026 · PMID 42157975
BACKGROUND: Patients with lymphoma frequently experience significant psychosocial burden, including anxiety, depression, and impaired quality of life, which may persist throughout the disease trajectory. Coping strategies and nurse-led care are recognized as important psychosocial determinants; however, their interrelationships remain insufficiently explored in lymphoma populations. OBJECTIVE: This study sought to assess psychosocial distress, coping strategies, and quality of life in patients with lymphoma, while …
Rank49.1
Dysphagia Outcomes Following Chimeric Antigen Receptor T-Cell (CAR-T) Treatment in Patients with Non-Hodgkin Lymphoma.
Cancer investigation · 2026 · PMID 41589322
INTRODUCTION: Dysphagia is a well-established complication in cancer patients, often resulting from chemoradiation-induced inflammation, fibrosis, and neuromuscular dysfunction. However, little is known about the incidence and clinical impact of dysphagia in patients undergoing adoptive cellular therapies such as Chimeric Antigen Receptor T-cell (CAR-T) therapy. AREAS COVERED: In this retrospective cohort study, we evaluated 116 patients with non-Hodgkin's lymphoma (NHL) who received CAR-T therapy between January 2…
Randomized Controlled Trials63 records
Rank106.7
Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.
The Lancet. Haematology · 2026 · PMID 41448213
BACKGROUND: The optimal treatment sequence for large B-cell lymphoma is unknown. We aimed to assess through meta-analysis the comparative effectiveness of bispecific antibodies (BsAb) after chimeric antigen receptor T-cell therapy (CAR-T) or CAR-T after BsAb. METHODS: We performed a systematic review and meta-analysis by searching MEDLINE and Embase from Jan 1, 2010, until Sept 16, 2025, and haematological conferences in 2024 and 2025 for studies assessing effectiveness of BsAb monotherapy or combination therapy af…
Rank106.7
CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.
La Clinica terapeutica · 2026 · PMID 42340791
BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a major therapeutic challenge, particularly among patients with high-risk molecular features or primary refractory disease. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment strategy; however, its comparative effectiveness versus salvage chemotherapy requires comprehensive evaluation. METHODS: This systematic review and meta-analysis were conducted in accordance with PRISMA 2020 and MOOSE guideli…
Rank106.7
Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.
Acta neurologica Belgica · 2026 · PMID 41212511
BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma, most often a diffuse large B-cell lymphoma. Rituximab, an anti-CD20 monoclonal antibody is widely used in PCNSL treatment but its efficacy remains uncertain. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy of rituximab in newly diagnosed adult PCNSL patients. METHODS: Medline/PubMed and Scopus were searched for studies comparing rituximab/rituximab-contai…
Rank106.4
Progression-free survival is strongly associated with overall survival in relapsed/refractory diffuse large B-cell lymphoma in the CAR T-cell era.
Journal of cancer policy · 2026 · PMID 41429401
INTRODUCTION: In clinical trials for diffuse large B-cell lymphoma (DLBCL), progression-free survival (PFS) has been used as a validated surrogate endpoint to help expedite drug development and regulatory approval. The advent of chimeric antigen receptor (CAR) T-cell therapies has radically changed the treatment landscape, potentially prolonging post-progression survival and weakening the correlation between PFS and overall survival (OS). This study evaluates the utility of PFS as a surrogate endpoint for OS in rel…
Rank106.2
Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis.
Cancer · 2026 · PMID 41701615
BACKGROUND: CD19-directed chimeric antigen receptor (CAR)-T-cell therapy has emerged as a second-line option for relapsed/refractory large B-cell lymphoma (R/R LBCL). However, its long-term benefits over standard of care (SOC) remain a matter of debate. METHODS: A systematic review and meta-analysis was performed of three randomized controlled trials (ZUMA-7, TRANSFORM, BELINDA) and one real-world comparative study evaluating second-line CAR-T versus standard-of-care chemoimmunotherapy (±autologous stem cell transp…
Rank103.2
Systemic Glucocorticoid Use and Risk of Site-Specific Cancers: A Methodologic Systematic Review of Observational Studies.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · PMID 41931525
Systemic glucocorticoids, widely prescribed for inflammatory and autoimmune diseases, have long been suspected of increasing cancer risk through immunosuppressive and metabolic effects. Randomized trials are often unethical and difficult to conduct, leaving observational studies the best option to determine whether the use of systemic glucocorticoids affects cancer development. However, these studies face significant methodologic issues that may compromise the validity of their findings. We systematically reviewed …
Rank102.6
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41260259
BACKGROUND: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase III randomized study in first-line therapy for DLBCL patients with adjusted-age international prognostic index (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after two cycles of R-CHOP to de-escalate treatment duration. PATIENTS AND METHODS: LNH2009-1B study is a two-arm, open-label, multicen…
Rank101.0
The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.
Hematological oncology · 2026 · PMID 42062177
The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B-cell lymphoma (DLBCL). Treatment consisted of six cycles of R-CHOP + 2xR or DA-EPOCH-R + 2xR. Patients with intermediate or high-risk CNS International Prognostic Index (CNS-IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m2 i.v. (arm A) or 6 doses of MTX 12 mg i.t. (arm B). P…
Rank100.3
Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.
Blood · 2026 · PMID 41347825
We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 …
Rank100.2
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
Lancet (London, England) · 2026 · PMID 42217458
BACKGROUND: Approximately 40% of patients with high-risk diffuse large B-cell lymphoma (DLBCL) are not cured with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone). We aimed to investigate the addition of tafasitamab (an Fc-enhanced anti-CD19 monoclonal antibody) and lenalidomide to R-CHOP (tafa-len-R-CHOP) in patients with high-risk aggressive B-cell lymphomas. METHODS: frontMIND is a phase 3, randomised, double-blind, placebo-controlled study conducted at 29…
Rank100.0
Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma.
Current research in translational medicine · 2026 · PMID 42184607
No recognized standard of care exists at the present time for treatment for large B-cell non-Hodgkin lymphoma that relapses or progresses after chimeric antigen receptor T-cell (CAR T-cell) therapy. Bispecific T-cell engagers (BiTEs) have emerged as an effective treatment for patients with relapsed or refractory (R/R) LBCL. The purpose of this systematic review and meta-analysis is to appraise the totality of evidence on the role of BiTEs as treatment for LBCL after CAR T-cell therapy failure. Results showed that p…
Rank99.9
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Lancet (London, England) · 2026 · PMID 42134356
BACKGROUND: Adding ibrutinib to standard, first-line immunochemotherapy improves failure-free survival in adult patients aged 18-65 years with mantle cell lymphoma, according to the first results from the TRIANGLE trial. With prolonged follow-up, we investigated whether the addition of autologous stem-cell transplantation (ASCT) to an ibrutinib-containing regimen improves failure-free survival, and evaluated effects on overall survival. METHODS: We conducted a three-arm, randomised, open-label, phase 3 superiority …
Rank99.6
A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465
BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…
Rank98.2
Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.
International journal of clinical oncology · 2026 · PMID 41989666
BACKGROUND: This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma. METHODS: In this double-blind, multicenter, randomized phase II study, 40 patients received hydroxyzine or bepotastine with acetaminophen 30 min before rituximab infusion. Primary endpoint was incidence of ≥ grade 2 IRRs based on the National…
Rank98.2
Mecapegfilgrastim for Prophylaxis of Immunochemotherapy-Induced Neutropenia in Patients With Diffuse Large B-Cell Lymphoma: A Multicenter Pilot Trial.
Cancer medicine · 2026 · PMID 42030265
BACKGROUND: This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy-induced neutropenia in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL). METHODS: In this open-label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no prophylaxis. All participants received 4 cycles of R-CHOP or R-CHOP-like regimens. The primary endpoint was the incidence of grade ≥ 3 neutropenia during cycle 1. RESULTS: Between O…
Rank98.1
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.
The Lancet. Haematology · 2026 · PMID 42285113
BACKGROUND: Anthracycline-free regimens are needed for older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We aim to evaluate the efficacy and safety of fixed-duration epcoritamab monotherapy versus epcoritamab with lenalidomide in this patient population. METHODS: This open-label, multicentre, randomised, phase 2 trial was conducted at 44 hospitals across 11 countries in Europe and Asia. Patients had newly diagnosed, histologically confirmed CD20-positive large B-cell lymphoma, were ineligible…
Rank98.0
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
Blood · 2026 · PMID 41915772
In the multinational, phase 3 RELEVANCE trial, 1030 patients with previously untreated follicular lymphoma were randomized to receive rituximab + lenalidomide (R2; n = 513) or rituximab-based immunochemotherapy (R-Chemo; n = 517). In the final analysis, at 120 months of follow-up, median progression-free survival (PFS) was comparable between the treatment groups: 110.6 months with R2 vs 102.8 months with R-Chemo, according to the independent review committee assessment. The 10-year PFS rates were 46.4% for R2 and 4…
Rank98.0
Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis.
Scientific reports · 2025 · PMID 40456850
Confirming the patient benefit of progression-free survival (PFS) in B-cell non-Hodgkin lymphoma (B-NHL) and multiple myeloma (MM) has become increasingly challenging due to the improved outcomes brought by novel therapies. In parallel, the U.S. Food and Drug Administration recommends conducting randomized trials, focusing on evaluating early endpoints to compare study and control arms for accelerated approval (AA). From both the clinical and regulatory perspectives, identifying early surrogate endpoints for PFS is…
Rank97.9
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
Blood · 2026 · PMID 40997297
Diffuse large B-cell lymphoma (DLBCL) poses a challenge in hematology given its varied symptoms, and the complex interplay between disease and treatment effects on health-related quality of life (HRQoL). The phase 3 POLARIX study demonstrated superior progression-free survival and a similar safety profile with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously unt…
Rank97.8
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
Lancet (London, England) · 2026 · PMID 41360064
BACKGROUND: Follicular lymphoma is characterised by episodes of remission and relapse, with patients requiring multiple lines of therapy. Lenalidomide plus rituximab is a commonly used immunotherapy combination in patients with relapsed or refractory follicular lymphoma. We aimed to assess the efficacy and safety of adding tafasitamab, a CD19-targeted Fc-enhanced monoclonal antibody, to lenalidomide and rituximab in this setting. METHODS: This phase 3, double-blind, randomised, placebo-controlled trial (inMIND) was…
Rank97.6
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Lancet (London, England) · 2026 · PMID 41371238
BACKGROUND: An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R2) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R2 versus R2 in participants with relapsed or refractory follicular lymphoma after at least one previous line of chemoimmunotherapy. METHODS: In this multicountry, open-label, phase 3 trial, participants were…
Rank97.4
Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.
Journal of patient-reported outcomes · 2026 · PMID 42329537
INTRODUCTION: Three patient-reported outcome (PRO) measures specific to lymphoma symptoms were previously defined using mixed-methods research, comprising questions from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and Item Library (IL): measures of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Symptoms, Mantle Cell Lymphoma (MCL) Symptoms, and an Expanded Fatigue measure. The objective of this study was to assess ps…
Rank97.3
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.
JAMA · 2026 · PMID 42018318
IMPORTANCE: Epigenetic dysregulation is associated with the pathogenesis and progression of diffuse large B-cell lymphoma (DLBCL). MYC/BCL2 double-expressor lymphoma (DEL), a distinct population of DLBCL defined by MYC and BCL2 coexpression, refers to poor prognosis after standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy. Tucidinostat (or chidamide), an oral, selective histone deacetylase inhibitor, has shown promising activity in DEL. OBJECTIVE: To evalu…
Rank97.0
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.
JAMA oncology · 2026 · PMID 41746629
IMPORTANCE: Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment. OBJECTIVE: To provide 15-year follow-up data from the SWOG S0016 trial that evaluated the potential for long-term remission and cure following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/prednisolone (CHOP)-based regimens. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, intergroup study was c…
Rank96.7
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
The Lancet. Haematology · 2026 · PMID 41651641
BACKGROUND: In advanced-stage cutaneous T-cell lymphoma (CTCL), current therapeutic options rarely provide long-lasting responses. We aimed to evaluate the efficacy and safety of a histone deacetylase inhibitor, resminostat, as maintenance therapy in patients with advanced-stage mycosis fungoides or Sézary syndrome, in whom disease control had been previously met. METHODS: We conducted a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial (RESMAIN) at 55 medical centres in Austria, Belgium, Fra…
Safety And Adverse Effects78 records
Rank106.9
Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.
Frontiers in immunology · 2026 · PMID 42495620
This meta-analysis compared chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), focusing on efficacy and safety. We analyzed 59 phase I/II trials involving 2,914 patients. CAR-T achieved higher ORR (72% [95% CI 67-77%] vs. 50% [38-62%]) and CR (54% [49-59%] vs. 33% [23-46%]) than BsAbs. However, it was associated with higher rates of grade ≥3 CRS (8% [6-11%] vs. 4% [3-7%]), ICANS (12% [9-16%] vs. 6% [2-18%]), and neuroto…
Rank105.6
Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.
Cancer · 2026 · PMID 42487493
BACKGROUND: Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, is a therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after chimeric antigen receptor T-cell therapy. This study summarized efficacy and safety across published cohorts. METHODS: The authors did a systematic review and meta-analysis of loncastuximab tesirine monotherapy in adults with relapsed or refractory DLBCL. They searched PubMed, Embase, and the Cochrane Library from inception to October 25, 2025, plus…
Rank105.5
Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352
INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …
Rank100.0
Exposure to municipal solid waste incinerators and cancer risk in surrounding populations: A systematic review and meta-analysis.
Environmental toxicology and pharmacology · 2026 · PMID 42324032
Evidence on the carcinogenic effects of municipal solid waste incinerators (MSWI) is inconsistent. This meta-analysis assessed associations between exposure to MSWI emissions and cancer risk. PubMed, Scopus, and Web of Science were searched for ecological, case-control, or cohort studies, evaluating cancer-related outcomes in populations exposed to MSWI. Study quality was evaluated. Random-effects meta-analyses were performed when at least three studies reported the same cancer outcome. Heterogeneity was assessed u…
Rank99.8
Clinical outcomes of Epstein-Barr virus infection/reactivation following CAR-T cell therapy: A systematic review.
Transplant immunology · 2026 · PMID 42442615
BACKGROUND: Epstein-Barr virus (EBV) infection or reactivation is an emerging but underrecognized complication following chimeric antigen receptor T-cell (CAR-T) therapy and is likely associated with treatment-induced immune dysregulation. Data regarding its clinical impact remain limited. OBJECTIVE: To evaluate the reported occurrence, clinical manifestations, and outcomes of EBV infection or reactivation in adults undergoing CAR-T therapy. METHODS: A systematic review was conducted in accordance with the PRISMA 2…
Rank99.6
A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465
BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…
Rank96.6
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.
International journal of clinical oncology · 2026 · PMID 42298056
BACKGROUND: Novel, accessible treatment options, are needed for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Mosunetuzumab, a T-cell-engaging bispecific antibody, plus polatuzumab vedotin, an antibody-drug conjugate, (Mosun-Pola), represents a novel fixed-duration outpatient therapy. The phase III SUNMO study (NCT05171647) demonstrated superior efficacy of Mosun-Pola versus rituximab plus gemcitabine-oxaliplatin (R-GemOx) in patients with R/R LBCL, with a manageable safety profile. We repor…
Rank95.8
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.
American journal of hematology · 2026 · PMID 42283231
Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun-Pola), with > 2 years of follow-up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun-Pola or R-Pola. Mosunetuzumab was administered subcutaneously with …
Rank95.2
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
The New England journal of medicine · 2026 · PMID 42341302
BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. METHODS: We evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 patients with large B-cell lymphoma and 14 with follicular lymphoma) who had been treated with CTL019 (now called tisagenlecleucel) - autologous T cells expressing CD19-directed, 4-1BB-costimula…
Rank89.3
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.
Nature medicine · 2026 · PMID 42463852
There is an unmet need for effective, off-the-shelf therapies for relapsed or refractory aggressive B cell non-Hodgkin lymphoma (B-NHL). Part 2 of the current study was an open-label, nonrandomized, phase 1 study of escalating doses of the CD19-4-1BBL co-stimulatory molecule, englumafusp alfa, in combination with glofitamab in patients with relapsed or refractory B-NHL. Obinutuzumab pretreatment was administered 7 days before the first glofitamab dose. Glofitamab step-up dosing in cycle 1 was followed by 11 cycles …
Rank88.9
Prophylactic PEG-rhG-CSF Reduces Febrile Neutropenia in Pediatric Hematological Malignancies Compared with Daily rhG-CSF.
Cancers · 2026 · PMID 42512281
Background: Febrile neutropenia (FN) is a major complication of chemotherapy in pediatric hematological malignancies. This study compared the efficacy and safety of prophylactic pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) versus daily short-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF). Methods: This single-center, open-label, randomized controlled trial was conducted at a tertiary children's hospital in China. Pediatric patients (<18 years) with confir…
Rank88.6
A Parent-Delivered Foot Bath Intervention for Chemotherapy-Related Fatigue in Children with Cancer: A Family-Centered Randomized Controlled Trial.
Children (Basel, Switzerland) · 2026 · PMID 42509946
Background/Objectives: Chemotherapy-related fatigue (CRF) affects 50-80% of children receiving chemotherapy and significantly impairs quality of life. Despite the family-centered care framework guiding pediatric oncology practice, evidence on parent-delivered, home-based non-pharmacological interventions for CRF remains limited. This study aimed to evaluate the effect of a parent-delivered warm-water foot bath on CRF in children aged 7-12 years undergoing chemotherapy. Methods: A two-arm parallel randomized control…
Rank88.3
Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study.
Advances in therapy · 2026 · PMID 42496861
INTRODUCTION: Rocbrutinib is a fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that binds covalently to the wild type BTK and non-covalently to the cysteine 481 mutant variant. This phase I study evaluated the pharmacokinetics (PK), safety, and efficacy of rocbrutinib in Chinese patients with relapsed or refractory (R/R) non-germinal center B cell-like (non-GCB) diffuse large B cell lymphoma (DLBCL). METHODS: Eligible participants were adults with non-GCB DLBCL and had received ≥ 2 prior lines of systemi…
Rank87.2
Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.
JAMA oncology · 2026 · PMID 42490071
IMPORTANCE: Interleukin (IL)-10 expressing CD19 chimeric antigen receptor (CAR) T cells (META 10-19) have demonstrated encouraging clinical activity in B-cell acute lymphoblastic leukemia, but their safety and efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remain unknown. OBJECTIVE: To evaluate the safety and efficacy of META 10-19 in patients with R/R DLBCL. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized, phase 1 clinical trial was conducted at the First Affiliated Hospital of Z…
Rank83.2
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
American journal of hematology · 2026 · PMID 42305039
First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. We conducted a phase 2 multicenter trial in the academic and community cancer research united (ACCRU) network, testing a multitargeted 1st line regimen. CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. The primary endpoint was complete metabolic response (CMR) rate. Secondary end…
Rank82.2
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
Oncoimmunology · 2026 · PMID 42415230
Patients with relapsed/refractory follicular lymphoma (R/R FL) often experience multiple disease recurrences with progressively shorter duration of remission. Chemoimmunotherapy (CIT) is commonly used for R/R FL in second-line and later settings but is not curative; novel, improved treatments are needed. Epcoritamab, a CD3 × CD20 bispecific antibody, is approved as monotherapy for R/R FL after ≥ 2 lines of therapy (LOTs) and combined with lenalidomide and rituximab (R2) for R/R FL. Epcoritamab + R2 pivotal data dem…
Rank81.2
Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42018969
PURPOSE: Peripheral T-cell lymphomas (PTCLs) are rare, heterogeneous, aggressive lymphomas. Five-year overall survival (OS) remains approximately 30%-40%, and most patients will develop relapsed or refractory (R/R) disease. Duvelisib is an oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ and PI3K-γ isoforms. Here, we report on the final analysis of the phase II PRIMO trial (ClinicalTrials.gov identifier: NCT03372057; Secura Bio, Inc) evaluating duvelisib monotherapy in R/R PTCL. METHODS: PRIMO was cond…
Rank80.2
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.
Nature communications · 2026 · PMID 42297808
Treatment options for relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) remain limited. In this phase 1b/2 trial (NCT05464433), we evaluated the safety and efficacy of liposomal mitoxantrone (Lipo-MIT) plus anti-PD-1 tislelizumab in this setting. During dose escalation, patients received Lipo-MIT (16 or 20 mg/m2) plus tislelizumab using a 3 + 3 design, followed by dose expansion at the recommended phase 2 dose (RP2D). The primary endpoint of the dose-escalation phase was dose-limiting tox…
Rank78.8
Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 41764665
BACKGROUND: Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment. AIMS: This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions. METHODS: HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospe…
Rank75.6
De Novo Cancer in Liver Transplant Patients With HIV Infection: A Multicenter Nationwide Cohort Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · PMID 41989878
BACKGROUND: Patients with human immunodeficiency virus (HIV) infection have been gradually accepted as solid organ transplant recipients, although there is still concern that the burden of immunosuppression and HIV infection could increase the risk of post-transplant cancer. METHODS: The risk of de novo cancer was evaluated in a prospective cohort of 272 HIV-positive and 816 matched HIV-negative liver transplant recipients in Spain (2002-2012). All tumors, except hepatocellular carcinoma recurrence and non-melanoma…
Rank75.0
Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.
Annals of medicine · 2026 · PMID 42482660
BACKGROUND: CD5-positive diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype with poor outcomes. Following the approval of Pola-R-CHP in China, this study aimed to evaluate its efficacy as initial therapy for this high-risk population. METHODS: We conducted a multicenter, retrospective study of previously untreated CD5-positive DLBCL patients who received Pola-R-CHP as first-line therapy between April 2023 and February 2025. Treatment response was assessed by PET/CT after 3 cycles and at the end of treat…
Rank74.2
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.
Leukemia & lymphoma · 2026 · PMID 41736495
To contextualize results from the single-arm ELM-2 study of odronextamab (CD20 × CD3 bispecific antibody) in relapsed/refractory (R/R) follicular lymphoma (FL) (N = 128), a post-hoc comparison was conducted versus third-line or later systemic therapies used in the real world (3L + RWST) in FLORA, a multinational, noninterventional study (N = 83; 100 lines of therapy). After weighting, objective response rate (80.5 vs. 52.7%; odds ratio [OR], 3.75 [95% CI, 1.98-7.11]), complete response rate (73.4 vs. 33.6%; OR, 5.3…
Rank74.0
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.
Journal for immunotherapy of cancer · 2022 · PMID 35750419
UNLABELLED: Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-Hodgkin's lymphomas, carry a worse prognosis for most subtypes when compared with their B-cell counterparts. Despite recent approval of newer therapies, the outlook for patients with relapsed/refractory (RR) PTCL remains poor and new treatment strategies are clearly needed. Targeting the profoundly immunosuppressive tumor microenvironment in PTCL is one such approach. To determine whether immune checkpoint blockade target…
Rank73.0
Incidence of lymphomas in a nationwide prospective cohort study of breast-implanted women.
Breast (Edinburgh, Scotland) · 2026 · PMID 42090861
BACKGROUND: The true incidence of Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare cancer associated with textured breast implants, remains uncertain due to limitations of implant exposure data and long-term follow-up. Concerns regarding other implant-associated malignancies are growing. This study aimed to determine the incidence of BIA-ALCL, non-BIA-ALCL lymphoma, and Breast Implant Associated-Squamous Cell Carcinoma (BIA-SCC). METHODS: 10,339 women with a first-time breast implantation…
Rank73.0
Comparative Risk of Adverse Cardiovascular Outcomes With Zanubrutinib Versus Ibrutinib in B-Cell Malignancies: A Large Real-World Propensity-Matched Analysis.
The American journal of cardiology · 2026 · PMID 42086088
Bruton tyrosine kinase inhibitors (BTKis) are foundational therapies for B-cell malignancies but are associated with clinically important cardiovascular toxicities. Ibrutinib has been linked to atrial fibrillation/flutter (AF/AFL), bleeding, and ventricular arrhythmias, whereas second-generation BTKis such as Zanubrutinib may confer improved cardiovascular safety. In this study, we aimed to compare adverse cardiovascular outcomes between zanubrutinib and ibrutinib in a large real-world cohort. We conducted a retros…
Treatments That Failed Clinical Trials60 records
Rank102.6
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41260259
BACKGROUND: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase III randomized study in first-line therapy for DLBCL patients with adjusted-age international prognostic index (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after two cycles of R-CHOP to de-escalate treatment duration. PATIENTS AND METHODS: LNH2009-1B study is a two-arm, open-label, multicen…
Rank99.9
Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.
Annals of hematology · 2025 · PMID 40397196
When different therapies provide similar cure rates, health-related quality of life (HRQoL) may become crucial for the choice of treatment. In the Positron Emission Tomography-guided Therapy of Aggressive non-Hodgkin Lymphomas (PETAL) trial, we compared six cycles of R-CHOP with or without two extra doses of rituximab in prognostically favorable interim PET (iPET)-negative patients, while eight cycles of R-CHOP were compared with two R-CHOP cycles followed by six cycles of a more intensive protocol in prognosticall…
Rank99.2
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
BMC cancer · 2024 · PMID 38267866
HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results from the open-label extension part. Patients were randomised to either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or HLX01 plus CHOP (H-CHOP) every 21 days for up to six cycles. The primary efficacy endpoint was overall survival (OS), and se…
Rank98.2
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.
Hepatology communications · 2025 · PMID 41335575
BACKGROUND AND AIMS: Immunosuppression can cause hepatitis B virus (HBV) reactivation, leading to severe outcomes in patients with "resolved" HBV infection. This multicenter, randomized, placebo-controlled trial assessed the efficacy of preemptive antiviral therapy in HBsAg-negative, anti-HBc-positive patients receiving rituximab-based chemotherapy for non-Hodgkin lymphoma (NHL). METHODS: Patients were randomized 1:1 to tenofovir alafenamide (TAF)/placebo across 3 phases: chemotherapy plus TAF/placebo (phase 1), TA…
Rank97.3
Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.
Blood advances · 2025 · PMID 40829107
In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma, benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients. The prognostic value of interim PET was assessed i…
Rank97.1
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.
Hematological oncology · 2022 · PMID 35858181
This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) and rituximab (Mabthera® ) combined with CHOP as the first-line treatment for Chinese patients with CD20-positive diffuse large B cell lymphoma (DLBCL). This is a randomized, patient-blind, multicenter, active-control, non-inferiority study with parallel design. Patients were randomly (2:1) to receive ripertamab combined with CHOP (S-CHOP) or rituximab (Mabthera® ) combined with CHOP (R-CHOP) for up to 6 cycles. The primary endpoint …
Rank97.0
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.
JAMA oncology · 2026 · PMID 41746629
IMPORTANCE: Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment. OBJECTIVE: To provide 15-year follow-up data from the SWOG S0016 trial that evaluated the potential for long-term remission and cure following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/prednisolone (CHOP)-based regimens. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, intergroup study was c…
Rank96.8
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
British journal of haematology · 2024 · PMID 37996986
Anti-CD20 antibody in combination with chemotherapy extends overall survival (OS) in untreated advanced-stage follicular lymphoma (FL), yet the optimal associated therapy is unclear. Data on the cumulative incidence of secondary malignancies postrelapse after conventional immunochemotherapy are scarce. A long-term analysis of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) as first-line treatment was conducted in a randomised clinical trial. A six-cycle R-CHOP regimen was …
Rank96.3
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
Blood · 2025 · PMID 40499012
Patients with follicular lymphoma who experience disease progression within 24 months of diagnosis (POD24) have a lower survival. Positron emission tomography (PET) response and circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at end of induction (EOI) may allow their early identification. A representative cohort of 141 patients from the RELEVANCE phase 3 trial with both available serum samples for ctDNA testing and PET images at randomization and at EOI (week 24) was investigated. Twelve per…
Rank96.3
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.
Current medical research and opinion · 2024 · PMID 39376156
OBJECTIVE: We report patient-reported outcomes (PROs) measuring health-related quality of life (HRQoL) from the ROSEWOOD trial (NCT03332017), which demonstrated superior efficacy and a manageable safety profile with zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) in patients with heavily pretreated relapsed/refractory follicular lymphoma (R/R FL). METHODS: PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) and E…
Rank96.2
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.
Blood advances · 2025 · PMID 40106688
We analyzed metabolic response using interim positron emission tomography scan (iPET) in a subset of patients with follicular lymphoma (FL) enrolled in the randomized FOLL12 trial. Patients with grade 1-3a FL with an iPET performed between cycles 4 and 5 of first-line immunochemotherapy (ICT) were included; PET scan had to be centrally reviewed for the definition of Deauville score (DS) and were considered positive for DS 4-5. Overall 123 patients out of 211 with iPET were available for central review. Of these, 43…
Rank95.9
Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
Cancer communications (London, England) · 2023 · PMID 37403255
BACKGROUND: The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) but whether the same efficacy can be achieved with reduced chemotherapy regimen of four cycles for non-bulky DLBCL patients with an IPI of 1 remains unclear. This study compared four cycles versus six cycles of chemotherapy in non-bulky low-risk DLBCL patients with ne…
Rank95.6
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.
EBioMedicine · 2024 · PMID 39631145
BACKGROUND: We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role of adjuvant rituximab and translational studies. METHODS: Patients with ESFL were randomised to involved field radiotherapy (IFRT) or IFRT plus 6-cycles cyclophosphamide/vincristine/prednisolone (IFRT + CVP). From 2006 rituximab was added to IFRT + CVP (IFRT + R-CVP). Clinical and multi-omic parameters were evaluated. Findings were validated in two indep…
Rank95.4
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.
Leukemia · 2024 · PMID 38538861
The role of consolidative radiotherapy (RT) for patients with aggressive B-cell lymphoma has not been fully elucidated. The R-MegaCHOEP trial investigated the use of high-dose chemotherapy and rituximab with subsequent autologous stem cell transplantations compared to conventional immunochemotherapy (R-CHOEP) for high-risk patients up to 60 years. The study protocol included RT for patients with bulky (maximum diameter ≥7.5 cm) or extranodal disease. Two-hundred sixty-one patients were analyzed, 120 of whom underwe…
Rank95.4
Endoscopic ultrasound (EUS) elastography-guided fine-needle aspiration cytology (FNAC) versus conventional EUS FNAC for solid pancreatic lesions: A pilot randomized trial.
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025 · PMID 39230660
BACKGROUND: Endoscopic ultrasound guided fine-needle aspiration (EUS FNA) is the first-line modality to diagnose suspected solid pancreatic malignant lesions. Elastography-guided FNA has been shown to improve the diagnostic yield of EUS FNA but prospective studies are limited. The aim of the study was to compare diagnostic accuracy, sensitivity and specificity of conventional and elastography-guided EUS FNA in patients with suspected malignant pancreatic solid masses. METHODS: Patients with suspected malignant soli…
Rank95.2
The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · PMID 37014666
PURPOSE: This study aims to investigate the relationship between the intensity of the initial treatment given to patients with de novo diffuse large B-cell lymphoma (DLBCL) and the impact of their baseline cell-free DNA (cfDNA) levels on their long-term survival. EXPERIMENTAL DESIGN: The GOELAMS 075 randomized clinical trial compared rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with high-dose R-chemotherapy plus autologous stem cell transplantation (R-HDT) for patients aged ≤60.…
Rank95.2
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL).
Cancer research and treatment · 2023 · PMID 35381164
PURPOSE: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin's lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-risk NHL. Moreover, the busulfan, cyclophosphamide, and etoposide (BuCE) conditioning regimen has been used widely in ASCT for NHL. Therefore, based on these encouraging results, this randomized phase II multicenter trial …
Rank95.2
Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma.
Hematological oncology · 2025 · PMID 41117344
Patients with Hodgkin lymphoma (HL) or peripheral T-cell lymphoma (PTCL) who relapse after high-dose chemotherapy (HDCT) have a dismal prognosis. Brentuximab-vedotin (BV) is a CD30-targeting antibody-drug-conjugate (ADC) used in first-line-, salvage-, and maintenance-therapy of HL, as well as first-line- and salvage-therapy of PTCL. In phase I of this trial, we could show that BV can safely be added to BeEAM-HDCT (bendamustine, etoposide, cytarabine and melphalan). Here, we report the randomized phase II part of th…
Rank95.0
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · PMID 38096461
PURPOSE: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial. PATIENTS AND METHODS: Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance …
Rank94.6
The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial.
British journal of haematology · 2025 · PMID 40419413
The UK National Cancer Research Institute (NCRI) phase 2 randomised CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T) trial compared the regimens of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) and gemcitabine, cisplatin and methylprednisolone (GEM-P) in treatment-naïve patients with peripheral T-cell lymphoma (PTCL). Evaluation of the role of positron emission tomography/computed tomography (PET/CT) was a key secondary end-point. All patients require…
Rank92.8
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial.
Scientific reports · 2024 · PMID 39043871
In the frontline high-dose phase 3 FIL-MCL0208 trial (NCT02354313), 8% of enrolled mantle cell lymphoma (MCL) patients could not be randomised to receive lenalidomide (LEN) maintenance vs observation after autologous stem cell transplantation (ASCT) due to inadequate hematological recovery and 52% of those who started LEN, needed a dose reduction due to toxicity. We therefore focused on the role played by CD34 + hematopoietic stem cells (PBSC) harvesting and reinfusion on toxicity and outcome. Overall, 90% (n = 245…
Rank92.6
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.
European journal of nuclear medicine and molecular imaging · 2024 · PMID 38795120
PURPOSE: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. METHODS: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy f…
Rank92.2
A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma.
Indian journal of cancer · 2023 · PMID 38185869
INTRODUCTION: Bendamustine-rituximab (BR) is the preferred regimen for the treatment of naïve follicular lymphoma (FL). Recently, lenalidomide-rituximab (LR), a chemotherapy-free protocol, has shown a good response rate in advanced FL. These regimens have never been compared in a randomized controlled trial for treatment-naïve FL in Indian patients. MATERIALS AND METHODS: This Phase III open-label randomized controlled trial was conducted to compare the efficacy and safety of BR and LR. Treatment-naïve patients old…
Rank92.0
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.
Leukemia · 2026 · PMID 41145670
The firstMIND trial (NCT04134936) evaluated the safety and efficacy of adding lenalidomide to R-CHOP+tafasitamab in the first-line treatment settings of patients with diffuse large B-cell lymphoma. To address response dynamics and the impact of measurable residual disease (MRD), we analyzed prospectively collected plasma samples from 56 study patients using the EuroClonality immunoglobulin gene (IG)-NGS assay. At baseline, disease-related clonotypes were identified in 50/56 (89%) patients by IG-NGS in cell-free (cf…
Rank91.9
Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Clinical and translational science · 2025 · PMID 40009571
E7777 is a therapeutic recombinant fusion protein comprised of diphtheria toxin fragments and human interleukin-2 (IL-2). Treatment with E7777 generates anti-drug antibodies (ADA). E7777-G000-302 assessed the efficacy and safety of E7777 in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Here, we describe the association between E7777 (at 9 μg/kg) and ADAs, and its effect on pharmacokinetics (PK), efficacy, and safety. Of 91 patients with immunogenicity results at baseline, 78.0% and 5.5% had…
i
Research information notice
Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.